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Acute venous disorders include deep venous thrombosis, superficial venous thrombophlebitis, and venous trauma. Deep
venous thrombosis (DVT) most often arises from the convergence of multiple genetic and acquired risk factors, with a
variable estimated incidence of 56 to 160 cases per 100,000 population per year. Acute thrombosis is followed by an
inflammatory response in the thrombus and vein wall leading to thrombus amplification, organization, and recanaliza-
tion. Clinically, there is an exponential decrease in thrombus load over the first 6 months, with most recanalization
occurring over the first 6 weeks after thrombosis. Pulmonary embolism (PE) and the post-thrombotic syndrome (PTS)
are the most important acute and chronic complications of DVT.
Despite the effectiveness of thromboembolism prophylaxis, appropriate measures are utilized in as few as one-third of
at-risk patients. Once established, the treatment of venous thromboembolism (VTE) has been defined by randomized
clinical trials, with appropriate anticoagulation constituting the mainstay of management. Despite its effectiveness in
preventing recurrent VTE, anticoagulation alone imperfectly protects against PTS. Although randomized trials are
currently lacking, at least some data suggests that catheter-directed thrombolysis or combined pharmaco-mechanical
thrombectomy can reduce post-thrombotic symptoms and improve quality of life after acute ileofemoral DVT. Inferior
vena caval filters continue to have a role among patients with contra-indications to, complications of, or failure of
anticoagulation. However, an expanded role for retrievable filters for relative indications has yet to be clearly established.
The incidence of superficial venous thrombophlebitis is likely under-reported, but it occurs in approximately 125,000
patients per year in the United States. Although the appropriate treatment remains controversial, recent investigations
suggest that anticoagulation may be more effective than ligation in preventing DVT and PE. Venous injuries are similarly
under-reported and the true incidence is unknown. Current recommendations include repair of injuries to the major
proximal veins. If repair not safe or possible, ligation should be performed. (J Vasc Surg 2007;46:25S-53S.)THE EPIDEMIOLOGY OF ACUTE DVT
The incidence of deep venous thrombosis (DVT) is
highly dependent on the population studied as well as the
means by which DVT is documented. It is generally be-
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doi:10.1016/j.jvs.2007.08.037lieved that incidence rates from epidemiological studies are
underestimates since autopsy studies indicate that up to
50% of venous thromboembolism (VTE) are not recog-
nized ante mortem. Community based studies of hospital-
ized patients have suggested an annual incidence of 56 per
100,0001 while population based studies of healthy volun-
teers have produced estimates of 122 per 100,000. Studies
of venographically confirmed DVT in Sweden have sug-
gested a somewhat higher incidence of 160 cases of new or
recurrent DVT per 100,000 population per year.2 Extrap-
olated to the population of the United States, this repre-
sents 116,000 to over 250,000 new cases of clinically
recognized DVT per year.1,3
Well-established risk factors for thrombosis are shown
(Table I). However, clinically manifest thrombosis most
often occurs with the convergence of multiple genetic and
acquired risk factors.4 Hospitalized patients have an aver-
age of 1.5 risk factors per patient, with 26% having three or
more risk factors.5 Multiple risk factors often act synergis-
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vidual risk factors. In symptomatic outpatients, the odds
ratio for an objectively documented DVT increases from
1.26 for one risk factor to 3.88 for three or more risk
factors.6
THE NATURAL HISTORY OF ACUTE DVT
Venous thrombogenesis
According to Virchow’s postulates, three factors are of
primary importance in the development of venous throm-
bosis – abnormalities of blood flow, abnormalities of blood,
and vessel wall injury. However, it is now clear that all three
components are not equally important in individual pa-
tients. Overt venous injury appears to be neither a necessary
or sufficient condition for thrombosis, although the role of
biologic injury to the endothelium is increasingly apparent.
Under conditions favoring thrombosis, the normally anti-
thrombogenic endothelium may become prothrombotic,
producing tissue factor, von Willebrand factor, and fi-
bronectin. Stasis alone is probably also an inadequate stim-
Table I. Thromboembolic risk factors
Risk factor Risk
Age Relative risk 1.9 per 10-year
increase
Surgery General surgery – 19%
Neurosurgery – 24%
Hip/knee – 48% – 61%
Trauma 58% of patients
Malignancy 15% of patients
History of VTE 2% to 9% of VTE patients
(40% of pts with Factor V
Leiden–2.4X)
Primary hypercoagulable states
AT, C&S deficiency 10X
Factor V Leiden
Heterozygous 8X
Homozygous 80X
Prothrombin 20210A 4X
Increased factor VIII 6X
Hyperhomocyst(e)inemia 2.5 – 4X
Family history 2.9X
Oral contraceptives 2.9X (30-50X with factor V
Leiden)
Estrogen replacement 2 – 4X
Immobilization 2X (pre-operative)
Pregnancy and puerperium Pregnancy – 0.075% of
pregnancies
Postpartum – 2.3 to 6.1 per
1000 deliveries
Femoral catheters 12% of trauma patients
Antiphospholipid antibodies Lupus anticoagulant – 6X
Anticardiolipin antibody –
2X
Inflammatory bowel disease 1.2 to 7.1% of patients
Obesity Variable
Varicose veins Variable
Myocardial infarction/CHF Variable
VTE, Venous thromboembolism; AT, antithrombin; C&S, Protein C and
protein S; CHF, Congestive heart failure.ulus in the absence of low levels of activated coagulationfactors.7 Although stasis may facilitate endothelial leuko-
cyte adhesion and cause endothelial hypoxia, its most im-
portant role may be in permitting the accumulation of
activated coagulation factors. Imbalanced activation of the
coagulation system appears to be the most important factor
underlying many episodes of acute DVT and is associated
with many thrombotic risk factors including age, malig-
nancy, surgery, trauma, primary hypercoagulable states,
pregnancy, and oral contraceptive use.
Lower extremity thrombi originate in areas where im-
balanced coagulation is localized by stasis – in the soleal
sinuses, behind venous valve pockets, and at venous con-
fluences. The calf veins are the most common site of origin,
although Browse showed that 40% of proximal thrombi
arose primarily in the femoral or iliac veins. If local condi-
tions favor propagation, laminated appositional growth
occurs outward from the apex as platelets are surrounded
by a red cell, fibrin, and leukocyte network.
After venous thrombosis, an acute to chronic inflam-
matory response occurs in the vein wall and thrombus
leading to thrombus amplification, organization, and
thrombus recanalization. The selectins (P- and E-selectin)
appear to be critically important in these processes. Selec-
tins are the first upregulated glycoproteins on activated
endothelial cells and platelets. In rat and mouse models of
inferior vena cava (IVC) thrombosis, the cell adhesion
molecule P-selectin has been found to be up-regulated in
the vein wall as early as 6 hours after thrombus induction,
while E-selectin was up-regulated at day 6, with increases in
gene expression preceding the protein elevations.8
The importance of the selectins in the inflammatory
and thrombotic response has been further defined using
genetically modified knock-out (KO) mice in which P-
selectin, E-selectin, or both were deleted. In these studies,
deletion of E-selectin and combined P-selectin/E-selectin
deletion was associated with decreased thrombosis, while
the vein wall inflammatory response was most inhibited in
the combined P-selectin/E-selectin and P-selectin KO
groups.
The importance of P-selectin and its receptor PSGL-1 has
also been demonstrated in a primate model of stasis-induced
IVC thrombosis produced by a temporary 6-hour balloon
occlusion. In this model, an antibody to P-selectin or a recep-
tor antagonist (termed rPSGL-Ig) inhibits inflammation and
thrombosis when given prophylactically.9,10 Further study has
demonstrated a significant dose-response relationship be-
tween rPSGL-Ig and thrombosis and rPSGL-Ig and sponta-
neous recanalization.11 No systemic anticoagulation, bleed-
ing time prolongation, thrombocytopenia, or wound healing
complications were found in rPSGL-Ig treated animals. Di-
rect selectin inhibition also effectively treats venous thrombo-
sis in a primate model of iliofemoral DVT formation.12
Selectin upregulation is associated with the formation
of microparticles (MP), fragments of phospholipid cell
membranes that promote coagulation and modulate a
number of inflammatory cell-vessel wall interactions. Plate-
let-derived MPs are involved in thrombosis in heparin-
induced thrombocytopenia.13 Less is known regarding leu-
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endothelial cell activation and cytokine gene induc-
tion.14,15 Additionally, MPs derived from endothelial cells
induce monocyte tissue factor (TF) antigen release and
increased expression.16
The thrombogenic potential of MPs is dependent on
TF expression and their anionic, prothrombotic surface
capable of assembling prothrombinase and tenase.17 The
influence of elevated levels of soluble P-selectin onMPs has
been studied using the delta CT mouse (^CT)18 which
demonstrates fourfold elevations in circulating soluble P-
selectin. A 50% to 60% increase in thrombusmass was noted
in this mouse in relation to IVC thrombosis at days 2 and 6
after thrombosis, and this increase was associated with the
occurrence of procoagulant MP in the circulation, most
prominent from leukocyte origin. Animals deficient in P-
selectin and E-selectin had decreased thrombosis and MPs.
These data suggest that with initial thrombosis, selectin
up-regulation leads to MP formation, which are then re-
cruited into the area of developing thrombosis, amplifying
the process. Selectin inhibition and combined P-selectin/
E-selectin gene deficiency results in less MP formation and
thrombosis. Fluorescent labeled MP injected intravenously
were found to be recruited into a growing thrombus in the
microcirculation of themouse cremasteric muscle, but were
not found in areas of the vessel free of thrombus.19 The
procoagulant nature of these MPs was demonstrated by
their ability to normalize bleeding in factor VIII deficient
mice. Additionally, there is growing evidence that blood
TF associated with leukocytes, or circulating in soluble
form, is also involved in venous thrombogenesis.20 Such
blood-borne capability may relate to MPs. However, de-
spite the existence of blood-borne TF, vessel wall TF ap-
pears to drive the formation of venous thrombosis in rodent
models of stasis-induced DVT.21
Thrombus resolution after acute DVT
Although once regarded as static structures that
changed little over time, it is clear that the venous lumen is
most often re-established after an episode of acute DVT. In
animal models of DVT, an early neutrophlic infiltrate ap-
pears within the thrombus followed by a predominantly
monocyte infiltrate by day 8.22 Monocytes may play a
particularly important role in thrombus organization and
recanalization, functioning as a source of both fibrinolytic
and cytokine mediators. Thrombus associated monocytes
also appear to be the primary source of both tissue-type
(t-PA) and urokinase-type plasminogen activators (u-PA)
andmay direct cytokine mediated neovascularization of the
thrombus.22,23 Cytokines, chemokines, and inflammatory
factors such as tumor necrosis factor alpha (TNF) facili-
tate inflammation. DVT resolution resembles wound heal-
ing and involves profibrotic growth factors, collagen depo-
sition and matrix metalloproteinase (MMP) expression and
activation.24-27
The fact that leukocytes invade the thrombus in a
specific sequence suggests their importance in the normal
thrombus resolution.28 The first cell type in the thrombusis the neutrophil (PMN), which may contribute both to
lysis as well as vein wall damage.29,30 Though PMNs may
cause vein wall injury, they are essential for early thrombus
resolution by promoting both fibrinolysis as well as collag-
enolysis. In a rat model of stasis DVT, neutropenia was
associated with larger thrombi at 2 and 7 days31 and was
correlated with increased thrombus fibrosis and signifi-
cantly lower thrombus levels of both u-PA and MMP-9.30
Stimulating the proinflammatory PMN response accel-
erates experimental DVT resolution. The chemotactic pep-
tide interleukin-8 (IL-8) accelerates thrombus resolu-
tion.32 It is speculated that IL-8 increases intrathrombus
PMN activation. Targeted deletion of the CXC receptor
(CXCR2 KO), whose ligands include KC and MIP-2 (an-
alogs of human IL-8), have been used to investigate the
role of chemokines in PMN influx into resolving mouse
thrombus.24 The CXCR2 KO mice had larger, less orga-
nized thrombi, fewer intrathrombus PMNs and fewer
monocytes over the first 8 days.33 Decreased late (day 12
and 21) thrombus neovascularization was also observed as
well as impaired fibrinolysis.
Despite the importance of PMNs in early thrombus
resolution, themonocyte is themost important cell for later
DVT resolution. Monocyte influx into the thrombus peaks
at day 8 after thrombogenesis, and correlates with elevated
MCP-1 levels, one of the primary CC chemokines that
direct monocyte chemotaxis and activation24,34 and which
has also been associated with DVT resolution.35 Targeted
deletion of CC receptor-2 (CCR-2 KO) in the mouse
model of stasis thrombosis was associated with late impair-
ment of thrombus resolution, probably via impaired
gamma interferon (gIFN) mediated MMP-2 and -9 activ-
ity. Indeed, CCR-2 KO mice with stasis thrombosis sup-
plemented with exogenous gIFN had full restoration of
thrombus resolution, in part due to recovery of MMP-2
and -9 activities, without an increase in thrombus mono-
cyte influx.
Healing tissue depends on physiologic neovasculariza-
tion. The aforementioned experiments with chemokine
receptor deleted-mice have confirmed a strong association
between thrombus resolution and neovascularization.
However, neovascularization may reflect thrombus organi-
zation and not impact thrombolysis. For example, in the rat
model of stasis DVT, no decrease in thrombus size was
found after exogenously administered pro-angiogenic
agents despite an increase in thrombus microvascular blood
flow.31 However, other investigators have found a poten-
tial role for vascular endothelial growth factor (VEGF) in
accelerating thrombus resolution when administered exog-
enously.36
As the thrombus resolves, numerous proinflammatory
factors, including IL-1, and TNF,28,33 are locally re-
leased. The cellular sources of these different mediators
have not been specifically defined but likely include leuko-
cytes and fibroblast-like cells within the resolving throm-
bus. The cellular leukocyte kinetics in the vein wall after
DVT is similar to what is observed in the thrombus with an
early influx of PMN, followed by monocytes. Based on the
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with partial recovery by 28 days, as measured by an increase
in vein wall stiffness (the inverse of compliance, a property
of normal veins). The increased vein wall stiffness continues
through 14 days and is accompanied by elevated MMP-2
and -9 activities.
Associated with this biomechanical injury from the
DVT is an elevation of profibrotic mediators including
TGF, RANTES, and MCP-1. Late fibrosis has been ob-
served in the mouse model of DVT with a significant
increase in vein wall collagen after stasis thrombogenesis.
Correlating with this increase in fibrosis is an increase in
collagen I and III gene expression as well as an increase in
MMP-2 and -9 gene expression and activity. The profi-
brotic growth factor TGF is also present in the thrombus
and is released with normal thrombolysis.37 This factor may
be one local mechanism promoting vein wall fibrosis. How-
ever, early vein wall collagenolysis (rather than collagen
production) seems to occur within the first 7 days in stasis
DVT in the rat model, representing an acute response to
injury. Ultimately, vein wall fibrosis may lead to vein valve
dysfunction, valvular reflux, and the syndrome of chronic
venous insufficiency.
Similar phenomena appear to occur in human thrombi,
recanalization occurring through a complex process involv-
ing intrinsic and extrinsic fibrinolysis, peripheral fragmen-
tation, neovascularization, and retraction.38,39 In the ab-
sence of propagation, the ultimate result is a restored
venous lumen with a slightly raised fibro-elastic plaque at
the site of initial thrombus adherence to the vein wall.
However, these processes may be accompanied by alter-
ations in vein wall compliance and the development of
valvular incompetence.
The clinical importance of these processes has been
confirmed in natural history studies employing serial ultra-
sonography. Among 21 patients prospectively followed
with ultrasound, Killewich40 noted that some recanaliza-
tion was present by 7 days in 44% of patients and by 90 days
in 100% of patients. Van Ramshorst41 similarly noted an
exponential decrease in thrombus load over the first 6
months after femoropopliteal thrombosis. Most recanaliza-
tion occurred within the first 6 weeks, with flow re-estab-
lished in 87% of 23 completely occluded segments during
this interval. These clinical observations suggest that recan-
alization begins early after an episode of acute DVT, with
the majority of thrombus regression occurring within the
first 3 months after the event. Approximately half of sub-
jects will show complete recanalization within 6 to 9
months of thrombosis.
Recurrent thrombotic events
Despite the importance of recanalization, recurrent
thrombotic events are also common. Clinical trials have
demonstrated symptomatic recurrent thromboembolic
events to occur in approximately 5% of patients treated with
standard anticoagulation measures for 3 months. Others
have noted a 13% cumulative incidence of symptomatic
recurrent thromboembolism 5 years after diagnosis. Prox-imal propagation has been similarly noted in approximately
20% of patients with untreated isolated calf vein thrombo-
sis. However, natural history studies have shown the inci-
dence of occult recurrent thrombotic events to be much
higher than the symptomatic events documented in clinical
trials. Serial duplex studies have demonstrated propagation
of thrombus in 26% to 38% of treated patients within the
first few weeks after presentation.42,43 In a larger series of
177 patients followed for a median of 9.3 months, recur-
rent thrombotic events were observed in 52% of patients.44
VTE occurring in conjunction with a major reversible
risk factor has a low risk of symptomatic recurrence: about
3% in the first year and 10% over 5 years. Patients who fall
into the category of idiopathic VTE without an inciting
etiology have a relatively high risk of recurrent disease,
about 10% in the first year and 30% over 5 years. Patients
with minor reversible risk factors associated with their VTE
have an intermediate risk of recurrence, approximately 5%
in the first year and 15% over 5 years.45,46 Thus, assessment
of clinical risk factors associated with the first episode of
VTE may provide useful prognostic information for recur-
rence. Interestingly, when a recurrent VTE event does
occur, it tends to manifest itself as the original event. That
is, pulmonary embolism (PE) begets recurrent PE and
DVT begets recurrent DVT.
COMPLICATIONS OF ACUTE DVT
Pulmonary embolism
PE occurs in approximately 10% of cases47 and is the
most important acute complication of DVT. Hospital dis-
charge data suggests an incidence of PE of 23 per 100,000
population.1 Mathematical estimates, based on a number
of assumptions, have suggested an incidence as high as
630,000 cases per year in the United States.48
VTE is therefore the fourth leading cause of death in
western society and the third leading cause of cardiovascu-
lar death behind myocardial infarction and stroke. Up to
10% of hospital deaths are due to PE, 76% occurring in
nonsurgical patients. VTE-related deaths exceed the com-
bined annual number of deaths in the United States attrib-
uted to breast cancer and AIDS. PE is also recognized as the
most frequent cause of maternal death associated with
childbirth.49 However, up to 75% of pulmonary emboli are
asymptomatic50,51 and as many as 25% to 52% patients with
documented DVT but no symptoms of pulmonary embo-
lism will have high probability lung scans.
The post-thrombotic syndrome
The post-thrombotic syndrome is the most important
late complication of acute DVT. Although some post-
thrombotic symptoms may be present in 29% to 79% of
patients, severe manifestations and ulceration occur in only
7% to 23% and 4% to 6% of patients, respectively.52-56
Population based studies have suggested that skin changes
and ulceration are present in 6 to 7 million and 400,000 to
500,000 people in the United States, respectively.3
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modynamic mechanism in chronic venous insufficiency,
may result from either venous reflux or persistent venous
obstruction. Although valvular incompetence appears to be
clinically more important, limbs developing edema, hyper-
pigmentation, or ulceration are more likely to have a com-
bination of reflux and residual obstruction than either
abnormality alone.57 Despite its importance, valvular dys-
function is not universal after acute DVT, reflux developing
in only 33% to 59% of involved venous segments.
The determinants of post-thrombotic manifestations
have been incompletely characterized but include the rate
of recanalization, recurrent thrombotic events, the global
extent of reflux and the anatomic distribution of reflux and
obstruction. Long-term ultrasound follow-up studies of
patients treated with standard anticoagulation measures
have demonstrated a relationship between the time to
complete recanalization and the development of reflux.58
Depending upon the venous segment involved, complete
recanalization required 2.3 to 7.3 times longer in segments
developing reflux than in segments in which valve function
was preserved.
Recurrent thrombotic events also have a detrimental
effect on valvular competence and development of the
post-thrombotic syndrome. Reflux has been observed in
36% to 73% of segments with rethrombosis, a considerably
higher rate than in segments without rethrombosis.44 Con-
sistent with these observations, recurrent thrombotic
events have been noted in 45% of patients with post-
thrombotic symptoms in comparison with only 17% of
asymptomatic subjects.47 Others have reported the risk of
post-thrombotic syndrome to be six times greater among
patients with recurrent thrombosis.54
The development of clinical signs and symptoms is also
related to the global extent of reflux and the anatomic
distribution of reflux and obstruction. Reflux in the distal
deep venous segments, particularly the popliteal and poste-
rior tibial veins, is most significantly associated with post-
thrombotic skin changes.59-61 However, superficial reflux
is also critically important and has been reported in 84% to
94% of patients with chronic skin changes and 60% to 100%
of patients with venous ulceration.
Mortality after acute DVT
Mortality after an episode of acute DVT exceeds that in
an age-matched population. Although the in hospital case-
fatality rate for DVT is only 5%, 3- and 5-year mortality
rates of 30% and 39%, respectively have been noted.1,47
Most deaths are related to malignancy or cardiovascular
disease.
PREVENTION OF VENOUS
THROMBOEMBOLISM: COMPLIANCE WITH
THE GUIDELINES
As discussed above, VTE represents a major cause of
morbidity and mortality in the United States.62-64 Most
cases of VTE occur in the peri-hospitalization period. In
the DVT Free registry, a large multicenter prospectiveultrasound study of 5451 patients, nearly 60% of VTE were
diagnosed within the peri-hospitalization period and 38%
occurred within 3 months of surgery.65 Furthermore, with
the evolution toward expanded outpatient delivery of med-
ical and surgical services, only the sickest and frailest of
patients are hospitalized. The VTE risk profile of contem-
porary hospitalized patients has therefore increased greatly
withmost carryingmore than one recognized risk factor for
VTE (Table I).
Without prophylaxis, VTE rates are high for both sur-
gical and nonsurgical hospitalized patients. Underscoring
the magnitude of this disease is the fact than more than 23
million operations are performed and more than 31 million
nonsurgical patients are admitted each year to US hospitals.
The incidence of VTE varies by both patient and procedure
specific variables; without prophylaxis, venous thrombotic
events may occur in up to 20% of surgical patients and 16%
of nonsurgical patients.66,67 Yet, venous thromboembo-
lism can be a preventable disease, particularly in the hospi-
talized patient.67 Appropriately delivered prophylaxis is
cost-effective, reduces VTE rates by 50% to 70% and carries
an acceptably low risk of hemorrhage.
For the vast majority of both surgical and nonsurgical
inpatients, extensive guidelines based on data from a large
numbers of randomized patients currently exist.67 These
guidelines are summarized in Table II and are available on
line for ready access to most physicians (www.chestjournal.
org/cgi/content/full/126/3_suppl/338S).
The practice of evidence-based medicine requires
both the awareness and access to these published guide-
lines as well as development and implementation of
disease-specific critical pathways within local institu-
tions.67,68 Unfortunately, the delivery of venous throm-
boembolism (VTE) prophylaxis is a prime example of the
disparities between published guidelines and the realities
of clinical practice. VTE prevention has become an im-
portant topic of national societies, foundations, and
healthcare agencies.67,69 Indeed, the appropriate deliv-
ery of VTE prophylaxis has been given the highest pri-
ority among other patient related safety interventions by
the Agency on Healthcare Research and Quality.69
Proper implementation of the guidelines has important
implications including: improved patient safety and out-
comes; improved education of house-staff, residents, and
students (those frequently writing the medical orders for
hospitalized patients); improved satisfaction of health
care providers knowing that they have adhered to the
latest and highest standards; reduced health care delivery
costs by reducing outcome events; and improved consis-
tency of healthcare delivery within and between institu-
tions.68 Furthermore, if the medical community fails to
champion this endeavor, regulatory agencies may link
compliance with reimbursement or other punitive
actions.70
The reality, however, is that many eligible patients in
clinical practice are not currently receiving appropriate pro-
phylaxis. Rates of delivery of appropriate VTE prophylaxis
vary from 29% to 56% and appear to be higher in academic
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Clinical Setting Recommendations
General Surgery
● Low risk: minor procedure 40 years, no risk factors* ● Early and frequent ambulation
● Moderate risk: minor procedure, 40–60 years, no risk factors
minor procedure, additional risk factors
major procedure, 40 years, no risk factors
● LDUH 5000 U BID or
● LMWH  3400 U once daily
● High risk: minor procedure, 60 years, no risk factors
major procedure, 40 years, additional risk factors
major procedure, additional risk factors
● LDUH 5000 U TID or
● LMWH  3400 U once daily
● High risk: minor procedure, 60 years, no risk factors
major procedure, 40 years, additional risk factors
major procedure, additional risk factors
● LDUH 5000 U TID or
● LMWH  3400 U once daily
● GCS/SCD for all patients
Gynecologic Surgery
● Low risk: minor procedure ( 30 minutes) ● Early ambulation
● Laparoscopic surgery: additional risk factors ● LDUH 5000 U BID or
● LMWH 3400 U once daily
● GCS/SCD
● Moderate risk: major procedure, benign disease, no risk factors ● LDUH 5000 U BID or
● LMWH  3400 U once daily
● High risk: major procedure for malignancy ● LDUH 5000 U TID or
● LMWH  3400 U once daily
● GCS/SCD
Urologic Surgery
● Low risk: minor procedure or transurethral procedure ● Early and frequent ambulation
● Moderate risk: major open procedure ● LDUH 5000 U BID (or TID) or
● GCS/SCD
● Moderate risk: major open procedure, high risk for bleeding ● GCS/SCD
● High risk: major procedure, additional risk factors ● LDUH 5000 U (BID or TID) or
● LMWH 3400 U once daily
● GCS/SCD for all patients
Orthopedic Surgery
● Elective hip arthroplasty ● LMWH  3400 U once daily
● fondaparinux
● warfarin (INR 2.0–3.0)
● Elective knee arthroplasty ● LMWH  3400 U once daily
● fondaparinux
● warfarin (INR 2.0–3.0)
● Elective knee arthroscopy: no risk factors ● Early ambulation
additional risk factors ● LMWH
● Hip fracture surgery ● LMWH  3400 U once daily
● fondaparinux
● warfarin (INR 2.0–3.0)
● Elective spine surgery: no risk factors ● Early ambulation
additional risk factors ● LDUH or
● LMWH once daily or
● GCS/SCD
Vascular Surgery
● Low risk: no risk factors* ● Early ambulation
● High risk major procedure, additional risk factors ● LDUH 5000 U BID or
● LMWH 3400 U once daily
Laparoscopic Surgery
● Low risk: no risk factors* ● Early ambulation
● High risk: additional risk factors ● LDUH 5000 U BID or
● LMWH 3400 U once daily or
● GCS/SCD
syndr
s cath
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numbers have improved little over the past decade.62,63,66 In
the contemporaryDVTFree registry, which gathered patients
with ultrasound confirmed DVT from 183 US medical cen-
ters, the vast majority (71%) received no antecedent prophy-
laxis therapy.65 In the International Medical Prevention Reg-
istry on Venous Thromboembolism (IMPROVE), which
assessed the clinical practice of VTE prophylaxis delivery in 21
hospitals across eight European and North American coun-
tries, only 37% of 1595 patients received prophylaxis.72 Rates
of prophylaxis delivery were comparable across continents,
whereas prophylaxis was provided in 38% and 44% for Euro-
pean and US patients, respectively.74
The presence of known risk factors also does not appear
to improve current prophylaxis delivery. In the DVT Free
study, neither a history of prior VTE, presence of malig-
nancy, need for malignancy related surgery, nor significant
obesity increased the use of prophylaxis.65,75 A significantly
larger proportion of patients with these risk factors did not
receive prophylaxis relative to those who did. Although one
might anticipate that medicine physicians would more ag-
gressively provide prophylaxis compared with their surgical
colleagues, the opposite is true. In this study, more than
twice as many surgical patients received prophylaxis relative
to medical patients (46.9% vs 22.2%). Furthermore, al-
though surgery is a well-known and potent risk factor for
Table II. Continued.
Clinical Setting
Neurosurgery
● Intracranial surgery
Major Trauma
● No active bleeding or
high risk for hemorrhage
● Active bleeding or high
risk for hemorrhage
● During rehabilitation
phase of recovery
● Spinal cord injury (acute
phase)
● Spinal cord injury (reha-
bilitative phase)
Medical Illness
● Acutely ill hospitalized and CHF, respi
or additional risk factors*
Contraindication to anticoag
LDUH, low dose unfractionated heparin; LMWH, low molecular weight h
Modified from Geerts et al. Chest 2004;126: 338S-400S.
Adapted from Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, C
Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;12
*Risk factors for venous thromboembolism: cancer, cancer therapy, previou
acute medical illness, congestive heart failure, respiratory failure, nephrotic
inflammatory bowel disease, obesity, smoking, varicose veins, central venouVTE, the vast majority (75%) of fatal PEs occur in nonsur-gical patients.76 Clearly, strategies for improved delivery of
VTE prophylaxis for both surgical and nonsurgical patients
alike are needed.
The reasons for low guideline compliance are many-
fold and unclear. The silent nature and late onset of VTE
relative to hospital discharge do not serve to reinforce the
use of prophylaxis. The use of prophylaxis is often not
rewarded since it is difficult to appreciate a thrombotic
event that does not occur. Furthermore, although printed
and electronic versions of prophylaxis guidelines are readily
available, the extremely thorough document may be a bit
daunting to digest in full and simply providing guidelines
has not been shown to improve compliance without active
promotion by specialists within the disease-specific field.77
Cited reasons for noncompliance include: simple oversight
of the guidelines: economic limitations; concerns for bleed-
ing; and unfamiliarity, nonendorsement or nonconsensus
of published guidelines.65 These reasons can largely be
divided into either challenges of education or system logis-
tics of implementation.
A number of strategies have been assessed with the goal
of improving clinician behavior and positively influencing
patient outcomes.78 These strategies have included both
passive and active information dissemination through con-
tinuing education; audit and feedback; computer based risk
assessment, ordering algorithms and automated reminders;
Recommendations
● GCS/SCD or
● LDUH or
● LMWH
● LMWH (begun when safe to do so)
● GCS/SCD if possible
● Screening DUS (if not possible)
● warfarin (INR 2.0–3.0) or
● LMWH once daily
● GCS/SCD
● LMWH (hemostasis ensured) or
● LDUH with GCS/SCD
● LMWH or
● warfarin (INR 2.0–3.0)
disease, bed rest ● LDUH or
● LMWH
ts ● GCS/SCD
; GCS, graduated support stockings; SCD, sequential compression device.
l CW, et al. Prevention of venous thromboembolism: The Seventh ACCP
S-400S.67
, increasing age, pregnancy and the postpartum period, hormonal therapy,
ome, myeloproliferative disorders, paroxysmal nocturnal hemoglobinuria,
eterization, inherited or acquired thrombophilia.ratory
ulan
eparin
olwel
6: 338
s VTEand quality assurance activities including the appointment
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Among 31 studies of such strategies, only one randomized
controlled study has been published. Most studies utilized
serial audits of compliance before and after initiation of the
intervention (Table III). Nineteen studies used a single
intervention and the remainder used multiple interven-
tions. None of these studies were adequately powered to
assess hard outcomes of VTE rates or mortality. Passive
information dissemination performed the least well with
less than 50% adherence to the guidelines. Active strategies
performed much better and computer based systems with
active automated reminders resulted in the highest success
rates. Multiple active strategies provided better outcomes
than single interventions. Interventions that allowed for
iterative refinement of the intervention through serial au-
dits provided the best results.
For many high-risk scenarios, randomized controlled
trial data has directly compared available agents, and both
risk and relative risk reduction percentages are currently
available. However, for many indications, neither the opti-
mal duration of anticoagulation prophylaxis nor the role of
combined pharmacologic agents and mechanical devices
(intermittent pneumatic compression, venous foot pump,
graduated compression stockings) is defined. Moreover,
the role of novel anticoagulants, such as oral direct throm-
bin, direct Factor Xa, or platelet inhibitors, and strategies
such as the use of retrievable inferior vena caval filters in
high risk patients has not been defined. Lastly, there are
several patient specific and surgical specific areas where the
precise recommendations for prophylaxis remain unclear.
Table III.
Author (Reference) Int
Ageno. Haematologica. 2002;87:746-50. PD
Arnold. Chest. 2001;120:1964-71. PD
Bratzler. Arch Intern Med. 1998;158:1909-12. PD
Williams. Post Grad Med. 2004;80:415-19. PD
Aouizerate. Therapie. 1998;53:101-6. AF
McEleny. Scott Med J. 1998;43:23-5. AF
Fagot. Presse Med. 2001;30:203-8. DA
Harinath. Ann Royal Coll Surg. 1998;80:347-9. DA
Durieux. JAMA. 2000;283:2816-21. CBDA
Macdonald. Can J Surg. 2002;45:47-52. CBDA
Patterson. Proc AMIA Symp 1998:573-6. CBDA
Taylor. Post Grad Med. 2000;76:354-6. CBDA
Anderson. Arch Intern Med. 1994;154:669-77. CME
Frankel. J Am Coll Surg. 1999;189:533-8. CME
Hall. Clin Perf Qual Health Care. 2000;8:72-82. CME
Peterson. J Clin Pharm Ther 1999;24:279-87. CME
Ryskamp. Chest. 1998;113:162-4. CME
Stratton. Arch Intern Med. 2000;160:334-40. PD, D
PD, passive dissemination; AF, audit and feedback; DA, documentation ai
QAA, quality assurance activities; AD, advertisement; RCR, retrospective ch
trial; PC, prospective cohort.
Modified from Tooher et al. Ann. Surg. 2005;241:297-415.
Adapted from Tooher R, Middleton P, Pham C, Fitridge R, Rowe S, Babi
thromboembolism in hospitals. Ann Surg 2005;241:397-415.These include patients undergoing elective spine surgery,patients suffering major burns, patients suffering spinal
cord injury, and patients with malignancy undergoing che-
motherapy.
TREATMENT OF VENOUS
THROMBOEMBOLISM
Anticoagulant drugs - heparin, low-molecular-weight
heparin (LMWH), and vitamin-k-antagonists (VKA) - are
the mainstays in management of VTE. Their appropriate
use is based upon the results of randomized clinical trials
and consensus recommendations reported in the Seventh
ACCP Conference on Antithrombotic Therapy and
Thrombolytic Therapy (Appendix). The recommendations
are based on the following rules of evidence which have
been adapted from the Seventh ACCP Conference on
Antithrombotic Therapy and Thrombolytic Therapy.79
Grade A: Consistent results from randomized clinical trials
(RCTs) generate Grade A recommendations,
Grade B: Inconsistent results from RCTs generate Grade B
recommendations,
Grade C: observational studies generate Grade C recom-
mendations, or secure generalizations from RCTs
Initial antithrombotic therapy
Unfractionated heparin. Clinical trials have estab-
lished the need for initial heparin (or LMWH) treatment in
patients with VTE.80 Classic anticoagulant therapy for
VTE was a combination of continuous intravenous heparin
using a heparin protocol81 and oral vitamin-k-antagonist
tion n Design
Outcome
(% compliance)
165 RCR 46.4
245 RCR 32.3
419 RCR 38
1534 RCR 33
1165 SA 81
1108 SA 97.4
279 SA 65
200 SA 79
1971 SA 95
4729 SA 62
2013 CC 99.3
529 SA 89.2
, DA 3158 RCT 52
, DA 200 SA 74
192 SA 75
DA 500 CC 70
209 PC 86
AA 4729 SA 62
DA, computer based decision aids; CME, continuing medical education;
views; SA, sequential audit; CC, case control; RCT, randomized controlled
, et al. A systematic review of strategies to improve prophylaxis for venouserven
, QAA
, QAA
, AD
, AD,
, QAA
A, Q
ds; CB
art re
dge W(VKA). Initial intravenous heparin therapy is administered
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range (2.0 to 3.0) for 2 consecutive days.80 Randomized
clinical trials have shown that achieving the lower limit of
the therapeutic range within 24 hours is required to ade-
quately prevent recurrent VTE for patients receiving hepa-
rin.82,83 Anticoagulant monitoring of UFH therapy is de-
scribed elsewhere.81
The main adverse effects of heparin therapy include
bleeding, thrombocytopenia, and osteoporosis.81,84,85 Pa-
tients at particular risk are those who have had recent
surgery or trauma, or who have other clinical factors which
predispose to bleeding, such as peptic ulcer, occult malig-
nancy, liver disease, hemostatic defects, obesity, age 65
years, and female gender. The development of thrombocy-
topenia may be accompanied by arterial or venous throm-
bosis that may lead to serious consequences including
death and limb amputation. Heparin must be stopped
immediately on the diagnosis of heparin-induced thrombo-
cytopenia (HIT).85 Alternate therapy, such as argatroban,
is required in patients requiring ongoing anticoagulation.
Osteoporosis has also been reported in patients receiving
UFH for more than 6 months. Demineralization can
progress to fractures of vertebral bodies or long bones, and
the defect may not be entirely reversible.81
Low-molecular-weight heparin. The LMWH given
by subcutaneous injection have distinct advantages over
continuous intravenous UFH including once-daily (or
twice-daily) subcutaneous administration and an anti-
thrombotic response that is highly correlated with body
weight, permitting administration of a fixed-dose without
laboratory monitoring. The use of LMWH has allowed
outpatient therapy in many patients with uncomplicated
DVT.80 As LMWHs have become widely available for
treatment, they have replaced intravenous UFH in the
initial management of most patients with VTE.
Evidence is accumulating that complications such as
bleeding, osteoporosis, and HIT are less serious and less
frequent with the use of LMWH when compared with
UFH.80 The LMWHs all cross-react with UFH and there-
fore cannot be used as alternative therapy in patients who
develop heparin-induced thrombocytopenia (HIT). Upon
diagnosis of HIT, LMWH must be stopped immediately85
and alternate therapy with agents such as argatroban insti-
tuted in patients requiring ongoing anticoagulation.
Fondaparinux. The synthetic pentasaccharide, fonda-
parinux, is effective for treating DVT and submassive PE.80
Thrombolytic therapy. Thrombolytic therapy re-
mains controversial due to the risk of bleeding and is not
indicated for the routine treatment of VTE. It is widely
accepted, however, that patients with acute massive PEmay
benefit from this adjunctive therapy.80 Thrombolytic ther-
apy for acute DVT is further discussed below.
Catheter interventions for pulmonary embo-
lism. Catheter-based devices for the extraction or the frag-
mentation of PE have the potential of producing immedi-
ate relief from massive PE. Such interventions may have a
role in patients in whom there is a contraindication to
thrombolytic therapy.Long-term antithrombotic therapy
Vitamin-k-antagonist therapy. The anticoagulant
effect of VKA is delayed until normal clotting factors are
cleared from the circulation, and the peak effect does not
occur until 36 to 72 hours after drug administration.86
Initial daily doses of 5 to 10 mg are preferred in initiating
vitamin-k-antagonist treatment; many clinicians advocate
starting with 5 mg. As the dose-response relationship to
vitamin-k-antagonist therapy varies widely between indi-
viduals, the dose must be carefully monitored to prevent
over- or under-dosing. A number of factors influence the
anticoagulant response to vitamin-k-antagonist therapy in
individual patients including dietary changes and drugs that
interfere with the metabolism of VKA.86 After 5 to 10 mg
per day for the first 2 days, the daily dose must be adjusted
according to the INR. Heparin or LMWH therapy is
discontinued on the fifth day following initiation of vita-
min-k-antagonist therapy, provided the INR is prolonged
into the recommended therapeutic range (INR 2.0 to 3.0)
for at least 2 consecutive days. Frequent INR determina-
tions are required initially to establish therapeutic
anticoagulation.80,86
Once requirements are stable, the INR should be mon-
itored every 1 to 3 weeks throughout the course of warfarin
therapy. However, if there are factors that may produce an
unpredictable response to warfarin (eg, concomitant drug
therapy), the INR should be monitored more frequently to
minimize the risk of complications.
Laboratory monitoring. In order to promote stan-
dardization of the PT for monitoring oral anticoagulant
therapy, the World Health Organization (WHO) devel-
oped an international-reference-thromboplastin from hu-
man-brain tissue and recommended that the PT ratio be
expressed as the International Normalized Ratio (INR).
The INR is the PT ratio obtained by testing a given sample
using the WHO reference thromboplastin. For practical
clinical purposes, the INR for a given plasma sample is
equivalent to the PT ratio obtained using a standardized
human brain thromboplastin known as the Manchester
Comparative Reagent, which has been widely used in the
United Kingdom. In recent years, thromboplastins with a
high sensitivity have been commonly used. In fact, many
centers have been using the recombinant tissue-factor that
has an ISI value 0.9 to 1.0 giving an INR equivalent to the
prothrombin-time ratio.86
Duration of anticoagulation. The duration of anti-
coagulant therapy is influenced by the knowledge of mul-
tiple parameters including whether it is a first episode vs a
recurrent episode of VTE; transient, continuing, or un-
known predisposing risk factors; and the risk of bleeding.
There is increasing awareness that venous thromboembo-
lism should be considered a chronic disease with a contin-
ued risk of VTE often associated with minor provocation.87
According to the guidelines developed by the American
College of Chest Physicians (ACCP), patients with a first
episode of VTE secondary to a transient (reversible) risk
factor should be treated initially with LMWH or unfrac-
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nist (VKA) continued for 3 months. The same regimen is
appropriate for patients with a first episode of idiopathic
VTE; however, LMWH or the VKA should be maintained
for at least 6 to 12 months. In fact, based on the results
from several large clinical trials, at least some data suggests
that patients with a first-episode of idiopathic DVT may
benefit from indefinite anticoagulant therapy.80
An individual’s risk for recurrent VTE is increased
substantially by a prominent family history of VTE with or
without identified inherited genetic thrombophilic risk fac-
tors;54 by the persistence of acquired precipitating throm-
bophilic disease states (cancer, antiphospholipid antibody
syndrome, etc); and by the presence of residual DVT
despite adequate anticoagulation therapy, typically noted
by serial duplexDoppler ultrasound examinations. Further-
more, the persistence of elevated plasma D-dimers levels
following completion of anticoagulation for the acute VTE
carries a poor prognosis for recurrent thrombotic
events.88,89
Despite the evidence-based guidelines, there will be
considerable uncertainty as to the duration of long-term
anticoagulant therapy in many patients. The decision to
implement extended anticoagulation should be based on
risk stratification for recurrent VTE and be placed in con-
text with potential hemorrhagic risks. It is also important to
include patient preferences in the decision-making process
concerning duration of anticoagulant therapy. In DVT or
PE patients who receive indefinite anticoagulant treatment,
the risk-benefit of continuing such treatment should be
reassessed in the individual patient at periodic intervals.
Where appropriate the patient should be involved in the
decision process.
Long-term low-molecular-weight heparin therapy.
Long-term LMWH has been compared with warfarin ther-
apy in patients presenting with VTE. Long-term LMWH is
a useful alternative to vitamin-k-antagonist therapy, and is
preferred therapy for up to approximately 6 months in
cancer patients with VTE.90
Summary
Based on a large number of level 1 clinical trials, the
accepted medical treatment for acute deep-vein thrombosis
has been established. Patients with established DVT or PE
require long-term anticoagulant therapy to prevent recur-
rent disease. Until recently, this consisted of UFH given by
continuous intravenous infusion with warfarin starting on
day 1 or 2 and continued for 3 months with a target INR of
2.0 to 3.0. More recently, a number of LMWHs have been
shown to be at least as effective as UFH in decreasing
recurrent VTE and are associated with less major bleeding.
LMWH has become the treatment of choice for both in
hospital and out of hospital treatment of DVT and, more
recently, PE as well.
Warfarin therapy is highly effective and is preferred for
long-term anticoagulation in most patients. The safety of
oral anticoagulant treatment depends heavily on the main-
tenance of a narrow therapeutic INR range (2.0 to 3.0).When the INR falls below the therapeutic range, the inci-
dence of recurrent VTE increases, whereas when the INR
exceeds a level of 3.5 to 5.0, the incidence of major hem-
orrhage markedly increases. The optimal duration of war-
farin anticoagulation after a first or recurrent episode of
venous thrombosis remains uncertain. Recent studies have
indicated that patients with a first episode of idiopathic
DVT require at least 6 months of long-term anticoagulant
treatment and patients who have a first recurrence require
at least 12 months of anticoagulant treatment. Because the
risk of recurrent VTE continues even after these extended
periods of treatment, future recommendations may be for
even longer periods of treatment. These and other unan-
swered questions related to themanagement of VTEwill be
further clarified by the results of ongoing clinical trials.
Adjusted-dose subcutaneous heparin has been the
treatment of choice where long-term oral anticoagulants
are contra-indicated, such as in pregnancy, but LMWH is
increasingly being considered. Adjusted-dose subcutane-
ous heparin, or unmonitored LMWH have been used for
the long-term treatment of patients in whom oral antico-
agulant therapy proves to be very difficult to control.
CATHETER-DIRECTED THROMBOLYSIS FOR
THE TREATMENT OF ACUTE DVT
Rationale for early thrombus removal
When deep vein thrombosis occurs, the goals of ther-
apy are (1) to prevent the extension or recurrence of the
deep venous thrombus and fatal pulmonary embolism (PE)
and (2) minimize the early and late sequelae of DVT.
Antithrombotic therapy can accomplish the former, but
contributes little or nothing to the second goal. Patients
with extensive DVT, exemplified by those with iliofemoral
involvement, can have progressive swelling of the leg lead-
ing to phlegmasia cerulea dolens (literally, painful blue
swelling) and also suffer the most severe post-thrombotic
morbidity.91,92 Iliofemoral DVT (IFVT) may also be asso-
ciated with increased compartmental pressure that can oc-
casionally, although rarely, progress to venous gangrene
and limb loss.
The clinical outcome after DVT can be categorized
into four subgroups: those with neither detectable obstruc-
tion nor valvular incompetence, those with obstruction
alone, those with valvular incompetence alone, and those
with both outflow obstruction and distal valvular incompe-
tence. However, it is often not appreciated that proximal
obstruction, even if ultimately relieved by partial recanali-
zation and/or collateral development, can lead to progres-
sive failure of distal valves, resulting in reflux. As the com-
bination of venous obstruction and valve incompetence is
associated with development of the post-thrombotic syn-
drome,57,93 it appears reasonable that if large vein throm-
bus can be cleared and rethrombosis avoided, patients will
benefit over the long term. Early thrombus removal might
also prevent some of the deleterious effects of vein wall
inflammation discussed above.
ytic th
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the proximal veins of the leg are (1) catheter-directed
thrombolysis (CDT), (2) thrombolysis combined with per-
cutaneous mechanical “thrombectomy” (CDT  PMT),
using one of a number of mechanical devices, and (3)
surgical thrombectomy (TE).
Clinical benefits of early thrombus removal
The potential benefits of early thrombus removal are
supported by experimental studies showing that thrombol-
ysis of acute venous thrombosis preserves venous valve and
endothelial function.94,95 These experimental findings are
consistent with natural history studies of patients with acute
DVT treated with anticoagulation.40,58,96 Furthermore,
when early (within 90 days) spontaneous lysis restored
venous patency, valvular function was frequently pre-
served.58
The benefit of thrombus removal has been docu-
mented in randomized trials of iliofemoral venous throm-
bectomy plus arteriovenous fistula and anticoagulation vs
anticoagulation alone in patients with iliofemoral
DVT.97-99 Follow-up at 6 months, 5 years, and 10 years
demonstrated obvious benefits among those randomized
to venous thrombectomy. Early thrombus removal resulted
in improved patency of the iliofemoral venous system,
lower venous pressures, less edema, and fewer post-throm-
botic symptoms. It appears that if early thrombus removal is
successful, patients will have significantly fewer post-
thrombotic sequelae.
Early trials of systemic thrombolytic therapy for proxi-
mal DVT showed that 50% of the patients had complete
lysis.100 However, those with successful lysis had signifi-
cantly reduced post-thrombotic morbidity and demon-
strated preservation of venous valve function. Unfortu-
nately, the clinical benefit was frequently lost amid the
significantly increased risks of major complications, pre-
dominantly bleeding.101 The risk of complications, as well
as the limited efficacy, of systemic thrombolysis has led to
Table IV. Efficacy and complications of catheter-directed
Bjarnasan102 (N  77) 
Initial success 79%
Iliac 63%
Femoral 40%
Primary patency (1 y)
Iliac 63% 
Femoral 40%
Iliac patency (1 y)
 Stent 54%
- Stent 75%
Major bleeding 5%
Intracranial bleeding 0%
Pulmonary embolism (PE) 1%
Fatal PE 0%
Death secondary to lysis 0%
*Death due to multiorgan failure 30 days post lysis; thought unrelated to lthe technique of catheter-directed thrombolysis.Intrathrombus catheter-directed thrombolysis
The conclusions from the studies cited above are clear:
early removal of the thrombus conveys significant benefits,
and the earlier the removal, the better the outcome. Cath-
eter-directed intrathrombus delivery of plasminogen acti-
vators theoretically accelerates thrombus resolution, in-
creasing the likelihood of success and diminishing bleeding
complications. When delivered into the thrombus, plas-
minogen activators efficiently activate fibrin-bound plas-
minogen, thereby generating plasmin that is protected
from circulating antiplasmins, predominantly 2-antiplas-
min.
Several reports suggest that initial lytic success can be
achieved in the majority of patients. Three of the largest
reports show an 80% to 85% success rate and relatively low
(and consistent) complication rates (Table IV).102-104 Ma-
jor bleeding complications, defined as puncture-site bleed-
ing, hematoma requiring evacuation, and the need for
blood transfusions, developed in approximately 5% to 10%
of patients. Symptomatic pulmonary embolism as a com-
plication of treatment is also rare. Mortality in these three
large studies was much less than 1%, indicating that proper
patient selection and thoughtful patient management can
offer significant benefit without substantial risk.
Case series also suggest an improved long-term outcome
following catheter-directed thrombolysis. The National Ve-
nous Registry showed an overall thrombosis-free survival in
65% of patients at 6 months and 60% at 12 months.104
Perhaps not surprisingly, thrombosis-free survival correlated
with the results of initial therapy. Seventy-five percent of
patients with complete thrombus resolution had patent veins
at 1 year compared with 37% of those in whom50% of the
clot was dissolved. The results were most favorable in the
subgroup of patients with acute, first-time iliofemoral DVT
who had successful lysis: 96% of the veins remained patent at 1
year. This emphasizes the importance of proper patient selec-
tion. Interestingly, 72% of the patients with complete lysis had
mbolysis with urokinase
Mewissen104 (N  287) Comerota103 (N  58)
83% 84%
64% 78%
47% -
64% 78%
47% -
74% 89%
53% 71%
11% 9%
1% 0%
1% 0%
0.2% 0%
0.4% 0% (*? 2%)
erapy.thronormal valve function.
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patient-perceived benefit and quality-of-life to be linked to
early phlebographic results. A validated quality-of-life ques-
tionnaire was used to compare the outcome in 68 patients
treated with catheter-directed urokinase with a similar
group of 30 patients treated contemporaneously with anti-
coagulation alone based on physician preference.105 All
patients were candidates for thrombolytic therapy. Those
treated with catheter-directed thrombolysis had a signifi-
cantly better quality of life at 16 and 22 months compared
with those treated with anticoagulation alone. Not surpris-
ingly, the quality-of-life results were directly related to the
initial success of thrombolysis. Patients who had a success-
ful lytic outcome reported a significantly better health
utilities index, better physical functioning, less stigma of
chronic venous disease, less health distress, and fewer post-
thrombotic symptoms. Patients with failed lysis and pa-
tients treated with anticoagulation alone had similar out-
comes.
A number of other case series have demonstrated ex-
cellent early success rates associated with minimal compli-
cations.106-108 Elsharawy109 has reported a small prospec-
tive randomized trial of catheter-directed thrombolysis vs
anticoagulation demonstrating improved patency rates and
fewer post-thrombotic symptoms in patients treated with
catheter-directed thrombolysis. Despite these favorable
outcomes, we now have the responsibility of showing that
early success is associated with long-term benefits in larger,
appropriately designed trials.
Technique of catheter-directed thrombolysis
The technique of catheter-directed thrombolysis for
iliofemoral DVT has evolved over the past decade. The
preferred approach uses an ultrasound-guided popliteal
vein puncture for antegrade passage of a long infusion
catheter. Adjunctive mechanical thrombectomy techniques
can be incorporated through this approach if desired. If the
popliteal vein is thrombosed, an additional catheter is
placed through an ultrasound-guided posterior tibial vein
puncture. This technique maximizes the chance of restor-
ing patency to the popliteal vein and providing optimal
venous inflow to the iliofemoral venous system once it is
cleared of acute thrombus.
During the past several years the volume of lytic infu-
sate has increased and the concentration of the plasmino-
gen activator decreased. Many now prefer to infuse 50 to
100 ml/h of a dilute plasminogen activator solution. The
large volume is intended to saturate the thrombus, expos-
ing more fibrin-bound plasminogen to the plasminogen
activator. Phlebograms obtained at 12-hour intervals are
used to monitor the lytic success. Vena caval filters are not
routinely used but are recommended for patients with
free-floating thrombus in the vena cava. Retrievable caval
filters can be used in the patients in whom only temporary
protection is needed.
Following successful thrombolysis, the venous system
is evaluated for areas of stenosis. Residual areas of stenosis
must be corrected to insure long-term patency. Such le-sions most frequently involve the left common iliac vein,
where it is compressed by the right common iliac artery.
Intravascular ultrasonography improves the evaluation of
iliac vein compression and the precision of any required
stent deployment. Common iliac vein stents should ap-
proach the diameter of the normal common iliac vein (12
mm or larger). Post-treatment therapeutic anticoagulation
is important to prevent recurrent thrombosis. The duration
of anticoagulation is being extended in these patients to no
less than 1 to 3 years. If an underlying hypercoagulable
state is identified or if the patient had a prior episode of
venous thrombosis, anticoagulation is continued indefi-
nitely. Single stents in the common iliac vein have been
associated with excellent patency.
SURGICAL AND ENDOVENOUS
THROMBECTOMY FOR ACUTE ILIOFEMORAL
THROMBOSIS
Prompt early removal of thrombus is indicated to avoid
late post-thrombotic syndrome (PTS) in active patients
with acute iliofemoral venous thrombosis (IFVT). The first
line of treatment is often catheter-directed thrombolysis
(CDT), or percutaneous mechanical thrombectomy
(PMT)  CDT, with or without adjunct procedures such
as angioplasty and stenting. When there are contraindica-
tions or failure to achieve catheter access or adequate lysis
by these techniques, surgical thrombectomy (TE) with a
temporary arteriovenous fistula (AVF) is an alternative in
appropriately selected patients, ie, active, healthy patients
with reasonable longevity and short duration of IFVT.
Although duplex scanning usually confirms the presence of
IFVT, a femoral venogram from the contralateral side (or
alternatively a CT or MR venogram) may be required to
visualize the inferior vena cava and determine the upper
extent of thrombus extension.
Percutaneous mechanical thrombectomy
More than 10 percutaneous devices are currently avail-
able for clearing thrombus from dialysis grafts, of which
only one is approved by the FDA for venous use. The
Angiojet (Possis Medical, Inc, Minneapolis, Minn) is
among the most commonly used PMT catheters and relies
on high pressure saline jets to create a Venturi effect that
disrupts thrombus and permits evacuation through the
catheter. Drawbacks include incomplete wall contact and
moderate to substantial blood loss and hemolysis. The
Trellis device (Bacchus Vascular, Inc, Santa Clara, Calif)
has been approved by the FDA and combines mechanical
and pharmacological thrombolysis. The thrombolytic drug
is contained between two occlusive balloons to prevent
undesired systemic effects and complications. The throm-
bolytic drug is infused into the thrombus between the
balloons and a wire rotates to mix and macerate the agent
and the thrombus. After maceration, the “liquid” throm-
bus by-products are suctioned and the balloons deflated.
Data from a multicenter registry110 comparing the two
devices demonstrated 50% thrombus removal in 77% of
patients (n  40) with a device run time of 191 seconds;
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75% and 26 minutes.
Sonolysis is a more recent technique that relies on the
interaction between high-energy ultrasound and perflutren
lipid microspheres infused into thrombus. High-energy
ultrasound is applied to the skin and sends an acoustic pulse
causing the microbubbles to cavitate; this microscopic “ex-
plosion” causes mechanical disruption of the thrombus.
Surgical thrombectomy
Technique. The technical aspects of venous throm-
bectomy has been detailed elsewhere.111 In this era of
endovascular surgery, there has been a rapid development
of adjunctive catheter-based procedures to improve the
results of TE including:
● Thomas Fogarty’s development of the balloon cathe-
ter 1966.
● Improved intraoperative diagnosis of iliac vein com-
pression (May-Thurner syndrome) or residual throm-
bus using venography, angioscopy, and intravascular
ultrasound (IVUS).
● Intraoperative management of residual stenosis by im-
mediate angioplasty and stenting of the iliac vein.
● Improved preservation of the femoro-popliteal valves
by combining proximal thrombectomy with intraop-
erative regional thrombolysis of the leg veins.112
● Prevention of fatal PE by temporary IVC filter before
removal of thrombus extending into the IVC.
● Postoperative arteriovenography after 6 weeks
through percutaneous catheterization of the contralat-
eral groin to check the arteriovenous fistula (AVF) and
thrombectomized iliac vein with possible angioplasty
and stenting of remaining iliac vein obstruction.113
● Percutaneous coil embolization of the temporary AVF.
Complications and results. Series of over 200 pa-
tients have reported venous thrombectomy to be associated
with no fatal perioperative PE and a mortality of less than
one percent. In a randomized clinical trial,51 perfusion lung
scans were positive on admission in 45% of all patients.
Additional defects were present after 1 and 4 weeks 11%
and 12% of the conservatively treated patients, respectively,
in comparison with 20% and 0% in the thrombectomy
group. When surgical thrombectomy was combined with a
temporary AVF, 13% had early re-thrombosis of the iliac
vein.98 Among randomized patients, venographic iliac vein
patency at 6 months was 76% in the surgical group com-
pared with 35% in the conservative group.98 This differ-
ences persisted after 5 and 10 years with 77% and 83%
patency in the surgical group, respectively, vs 30% and 41%
in the conservative group.97,99 Femoropopliteal valve com-
petence at 6 months, determined by descending venogra-
phy with valsalva, was significantly better in the surgical
group (52%) compared with the conservatively treated
group (26%).98 Combining the results of all functional
tests, 36% of the surgical patients had normal venous func-
tion after 5 years in comparison with 11% of the conserva-
tively treated group.97 Unfortunately, these differenceswere not statistically significant due to loss of patients. At
10 years, duplex detected popliteal reflux was present in
32% of the surgical patients compared with 67% of the
conservative group.99
INDICATIONS AND TECHNIQUES OF
INFERIOR VENA CAVA INTERRUPTION
Indications
To understand the role of the inferior vena-cava-filter in
patients with VTE, it is important to consider the natural
history of VTE. Patients with untreated proximal venous
thrombosis, with or without PE, have a poor prognosis off
therapy: intervention is required.What line-of-defence can be
offered the patientwith proximal venous thrombosis or PE for
whom immediate anticoagulant therapy is contraindicated
due to hemorrhagic complications or who have an unaccept-
able risk of bleeding? Since the early 1970s, the answer has
been insertion of an inferior vena-cava-filter, the use of which
is less harmful to the patient than inferior vena-cava ligation.
The clinical use of the inferior vena-cava-filter has markedly
increased over the past two decades; indeed by the late 1990s
at least 30,000 to 40,000 filters were inserted in patients
annually in the United States.114,115
Since 1972, the categorical and most common indica-
tions for placement have been based on problems with
anticoagulation in patients with venous thrombosis (DVT),
either because it was contraindicated, had caused a compli-
cation forcing it to be discontinued, or had failed allowing
DVT progression or PE.116 Filters have been less com-
monly used after pulmonary embolectomy and in conjunc-
tion with anticoagulation for optimal protection in very
high-risk patients such as those with severe cardiac or
pulmonary disease. Placement of a second suprarenal filter
has also been successful when an existing filter has become
filled with thrombus or thrombus has propagated through
a filter. Suprarenal filters have similarly been placed for
thrombus up to or within the renal veins and in pregnant
patients to avoid the area of the cava compressed by the
gravid uterus.117 Filters have also been placed in the supe-
rior vena cava for propagating subclavian vein thrombosis
with PE.118
Over time, the success achieved with filters expanded
the indications in some series to prophylaxis for free-float-
ing thrombi longer than 5 cm;119 situations where the risk
of anticoagulation was felt to be excessive as in older
patients with DVT or following major trauma;120 and to
high risk situations such as orthopedic and bariatric opera-
tions.121 The risk of epidural hematoma from prophylactic
anticoagulation has added support for perioperative filter
placement in high-risk patients undergoing epidural anes-
thesia. Statistical data to support these indications are lack-
ing, and enthusiasm for expanded indications has declined
with case reports of late complications of caval occlusion
and filter fractures.
However, the development of retrievable filters has
rekindled their use for relative indications, particularly
short-term periods of increased risk such as duringmechan-
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tunately, data to date show equivalent complications, less
secure fixation, and the added expense of multiple proce-
dures. Improvements in techniques and devices should
overcome some of these limitations, but not the fundamen-
tal problem of knowing when the protection is no longer
needed.
Contraindications and abuse of filters
The current FDA guidelines suggest that sepsis be
considered a contraindication to filter placement. But long-
term experience with Greenfield filters indicates that such
wire-based devices can be used successfully since none has
required removal. Experimental studies show that only the
trapped thrombus can be infected, and that intravenous
antibiotics can sterilize it.123 Based on the 30 mm resting
diameter of the original Greenfield filter, FDA guidelines
also call for measurement of the vena cava prior to filter
placement to avoid cavas larger than 28 mm in diameter.
However, newer filters have larger resting diameters, and
the Bird’s Nest filter can be inserted into vena cavas as large
as 40 mm in diameter.
The use of filters in terminally ill patients with multi-
system organ failure may represent abuse of the indications
since virtually all die during hospitalization. Appropriate
use in patients with limited life expectancy should include a
risk-benefit assessment as well as the wishes of the patient
and family. The presence of orders against resuscitation
should preclude filter use.
Techniques for filter insertion
Percutaneous techniques for filter placement have
evolved to utilize smaller sheaths, allowing upper extremity
venous access when necessary in anticoagulated patients.
The focus on ease of access has overshadowed improve-
ments in design, often sacrificing security of fixation for
smaller profile. Similarly, the rush to embrace retrievable
filters has overlooked an obligatory reduction in fixation
security, since retrieval depends on easier detachment from
the caval wall. Frequently, permanent filters are trans-
formed to retrievable by removing hooks or limbs from the
device, adding to the risk of migration. Migration, with
reported fatal outcomes, has been reported and led to at
least one FDA warning.
Traditional access for filter placement has been the
right femoral vein, but its frequent involvement with
thrombus and the straighter route from the right jugular
vein to the inferior vena cava has led to increased preference
for this approach. Using real-time ultrasound guidance
increases the success of first pass cannulation and reduces
inadvertent arterial puncture. Guidewire passage through
the heart into the inferior vena cava may be difficult with a
prominent Eustachian valve, but an angled catheter can
facilitate the entry. Similarly, access from the left femoral
vein is more difficult than the right since it joins the vena
cava at a more oblique angle.
Radiographic imaging with fixed or mobile fluoroscopy
has been the traditional method for measurement of cavalsize and filter placement. But logistical difficulty in moving
critically ill patients, particularly those on respirators or
requiring intensive-care monitoring, has led to newer tech-
niques for bedside placement. Transabdominal duplex ul-
trasound has been the most common alternative imaging
modality, but is often inadequate in the face of obesity,
overlying bowel gas and open abdominal wounds. In these
situations, IVUS has been more successful in vena caval
visualization.124,125 This technique involves insertion of
the IVUS catheter to the level of the right atrium and
pullback to identify venous anatomical landmarks. Once
the appropriate vena caval site is identified, the filter carrier
can be inserted through a separate percutaneous puncture
site in the same or opposite femoral vein. More recent
modification of the technique allows insertion through a
single puncture by matching the length of the IVUS probe,
placed through the larger filter insertion sheath, to the
length of the filter carrier catheter. Further refinements in
imaging techniques and in the design of filters and their
delivery systems should make bedside insertion progres-
sively safer and easier.
HYPERCOAGULABLE STATES AND
MOLECULAR MARKERS IN VENOUS
THROMBOSIS
Hypercoagulable states
At least 50% to 70% of individuals with idiopathic VTE
have underlying thrombophilic defects.126 Such defects
may be either congenital or acquired. The relative risks of
developing a first episode of VTE in individuals with doc-
umented acquired or genetic thrombophilic predisposi-
Table V. Estimated relative risks for a first episode of
venous thromboembolism (VTE)*
Thrombophilic defect
Relative
risk References
Antithrombin deficiency 8–10 226,227
Protein C deficiency 7–10 226,227
Protein S deficiency 8–10 226,227
Factor V Leiden/APC
resistance
3–7 228,229
Prothrombin 20210A mutation 3 230
Factor V Leiden and
prothrombin 20210A
20 231
Elevated factor VIII:c (dose-
dependent)
2–11 232,233
Elevated factor IX:c 2–3 234
Elevated factor XI:c (90th
percentile)
2 235
Mild hyperhomocysteinemia 2.5–2.6 236
Anticardiolipin antibodies 237
All 1.6
High titers 3.2
Lupus anticoagulant 11
Adapted from Weitz JI, Middeldorp S, Geertz W, Heit JA. Thrombophilia
and anticoagulation drugs. American Society of Hematology education
book, 2004.
*Individuals with a thrombophilic defect compared with individuals without
a defect; derived from family and population-based case-control studies.tions are increased from two- to 11-fold (Table V).
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part include deficiencies of antithrombin, protein C, and
protein S; activated protein C resistance (which is predom-
inantly associated with the factor V Leiden gene R506Q
mutation); mutated polymorphisms in the prothrombin
gene (G20210A) and the methylentetrahydrofolate reduc-
tase gene (homozygous C677T or compound heterozy-
gous for C677T and A1298C) with hyperhomocysteine-
mia; and elevated levels of various clotting factors
(including factors VIII, IX, and XI). The most common
acquired thrombophilic disorders include the antiphospho-
lipid antibody syndrome, composed of a heterogeneous
group of autoimmune antibodies (anticardiolipin/an-
tiphospholipid antibodies and/or anti-2 glycopropro-
tein-1 antibodies), which functionally express themselves in
vitro as a circulating lupus anticoagulant and in vivo as a
thrombophilic state; hyperhomocysteinemia secondary to
deficiencies of folic acid, vitamin B6, and vitamin B12;
hyperviscosity syndromes, such as polycythemia rubra vera
and Waldenstrom’s macroglobulinemia; paroxysmal noc-
turnal hemoglobinuria; and vasculitis.
Among the inherited thrombophilias, the factor V Lei-
den gene mutation is the most common predisposing risk
factor, accounting for 40% to 50% of VTE in large popula-
tion studies. However, most factor V Leiden carriers do not
develop VTE and the incidence of VTE due to factor V
Leiden increases with age, in contrast to the other heredi-
tary thrombophilias, which usually manifest clinically by
young adulthood. Resistance to activated protein C, a
common risk factor for VTE noted in the laboratory, is
attributable to factor V Leiden in up to 95% of cases;
however, other factor V polymorphisms and elevated factor
VIII levels also have been implicated to produce this labo-
ratory phenomenon.
The prothrombin gene mutation and deficiencies in
protein S, protein C, and antithrombin account for most of
the remaining inherited thrombophilias. Extremely rare
genetic causes of thrombophilia include hypo-dysplasmi-
nogenemia and dysfibrinogenemia.127,128 The prevalence
of the factor V Leiden and the prothrombin geneG20210A
mutation varies according to ethnicity, from 2% to 7% and
1% to 3% in the general Caucasian population, respectively.
Themutations of these two genes are much less common in
African-Americans, and are unusual in ethnically pure
Asians and Africans.129,130 Known genetic risk factors for
VTE are rare in African-American, African, and Asian pop-
ulations, underscoring the need to explore for additional
unique gene polymorphisms. Possible candidate genes in-
clude polymorphisms for factor VII, thrombopoietin, and
platelet glycoprotein IIb/IIIa A1/A2 or A2/A2 muta-
tions.
These genetic risk factors are predominantly associated
with VTE rather than arterial thrombotic events although a
recent report has indicated that the presence of factor V
Leiden increases the risk of Ml in young Turkish men.131
Hyperhomocysteinemia secondary to MTHFR gene muta-
tions and plasminogen activator inhibitor type-1 inhibitor
gene polymorphisms are associated with both arterial andvenous thrombotic complications, and hyperlipoprotein-
emia (a) is associated overwhelmingly with arterial events.
Acquired thrombophilic states, associated with the an-
tiphospholipid antibody syndrome, cancer, etc. are associ-
ated with both arterial and venous hypercoagulable events.
Although thrombophilic defects are a well-established
risk factor for a first episode of VTE, their association to
VTE recurrence is somewhat controversial (Table VI).132
The published data do not consistently support the impor-
tance of antithrombin, protein C, or protein S deficiency,
heterozygous factor V Leiden mutation, or prothrombin
gene mutations in VTE recurrence. Mild hyperhomocys-
teinemia increases the risk of VTE recurrence moderately.
Patients with factor VIII levels persistently above the 90th
percentile; the lupus anticoagulant or antiphospholipid an-
tibodies; homozygous factor V Leiden mutation; or com-
pound heterozygous factor V Leiden and prothrombin
gene mutations have the highest risk of VTE recurrence.
Screening for hypercoagulability
The incidence of the genetic thrombophilic defects in
asymptomatic people is too low to make screening of the
general population cost-effective. In unselected patients
who have had a first episode of idiopathic VTE, testing for
heritable thrombophilia does not usually provide helpful or
prognostic information with respect to recurrent VTE after
anticoagulant therapy is stopped.45 Neither does routine
testing of patients with idiopathic VTE for thrombophilic
defects improve patient management. However, selected
populations of patients may benefit from thrombophilic
screening. For example, women with a personal history of
VTE or recurrent spontaneous miscarriages who wish to
become pregnant again; and men with a history of personal
idiopathic VTE whose daughters wish to initiate oral estro-
gen birth control pills. Many physicians would advise
women with strong family histories of hypercoagulable
events not to initiate estrogen birth control pills or to
pursue pregnancy. However, in a prospective study of 125
Table VI. Estimated relative risks for recurrent venous
thromboembolism (VTE)
Thrombophilic defect
Relative
risk References
Antithrombin, protein C or S
deficiency
2.5 238-240
Factor V Leiden mutation 1.4 45, 241-246
Homozygous factor V Leiden
mutation
4.1 132
Prothrombin 20210A mutation 1.4 45, 247-250
Heterozygous factor V Leiden
& 20210A
2–5 251
Elevated levels of factor VIII:c 6–11 233, 252
Mild hyperhomocysteinemia 2.6–3.1 253, 254
Antiphospholipid antibodies 2–9 255-257
Adapted from Weitz JI, Middeldorp S, Geertz W, Heit JA. Thrombophilia
and anticoagulation drugs. American Society of Hematology education
book, 2004.pregnant women with a history of isolated VTE and no
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those without a detectable underlying inheritable throm-
bophilic state and whose previous VTE was associated with
a temporary risk factor.133 In contrast, among women with
a history of idiopathic VTE, the incidence of recurrent VTE
was 7.7% and 13% in those with combined underlying
thrombophilic defects and idiopathic VTE, respectively.
Another special population that experiences increased
incidence of VTE is cancer patients. Hypercoagulability
may be produced by the intrinsic properties of the malig-
nancy or by effects of chemotherapy, leading to dissemi-
nated intravascular coagulopathy with arterial and/or ve-
nous thrombotic complications. The association of factor V
Leiden and the prothrombin 20210A variant with the VTE
in cancer patients has not been established. Several small
studies suggest that factor V Leiden conveys no increased
thrombophilic risk to the cancer patient, while one recent
publication noted greater than a sixfold increased risk for
VTE in the cancer patient with the heterozygous pro-
thrombin 20210A gene mutation.134 Thus, genetic screen-
ing of all cancer patients may not be necessary if VTE
prophylaxis is to be instituted in any case to protect against
the intrinsic hypercoagulable potential of the tumor itself.
The screening of asymptomatic family members of
hypercoagulable patients also provides an ethical challenge
to the physician and to society. Awareness of a genetic
abnormality, which may predispose to morbidity and pos-
sible mortality by VTE, would justify the initiation of
prophylactic antithrombotic treatment measures for high-
risk clinical situations. Unfortunately, many such individu-
als have been prevented from acquiring life insurance,
disability insurance, and long-term care insurance or have
been rated as unfavorable risks with attendant prohibitively
high premiums if they have knowledge of their abnormal
genome. Thus, it is difficult to recommend liberal genetic
screening of asymptomatic members of a thrombophilic
family unless the benefit-to-risk ratio is overwhelmingly
favorable to that individual.
In summary, thrombophilic screening should be indi-
vidualized. For those without a prior history of VTE but
with an anticipated reversible risk factor for VTE (such as
abdominopelvic surgery) and a compellingly positive family
history of VTE, screening may be reasonable so that appro-
priate VTE prophylaxis can be initiated. Similarly, women
who are habitual aborters with or without evidence of
placental vessel thromboses, may benefit from genetic
screening for thrombophilia. Finally, if the duration of
anticoagulant management of a previous VTE will be mod-
ified dependent on the presence of inherited thrombophilic
risk factors, genetic screening is justified.
SUPERFICIAL THROMBOPHLEBITIS
Although superficial venous thrombophlebitis (SVT) is
a relatively common disorder with a significant incidence of
recurrence and potential morbidity from extension and
pulmonary embolism (PE),135 it has been considered the
stepchild of DVT and received limited attention in the
literature. It has been reported that acute SVT occurs inapproximately 125,000 people in the United States per
year.136 However, the actual incidence of SVT is likely far
greater as these statistics may be outdated and many cases
go unreported. Traditional teaching mistakenly suggests
that SVT is a self-limiting process of little consequence and
small risk, leading some physicians to dismiss these patients
with the clinical diagnosis of SVT and to treat them with
”benign neglect.
Clinical presentation
Approximately 35% to 46% of patients with SVT are
males, with an average age of 54 years old. The average age
for females is about 58 years old.137,138 The most frequent
predisposing risk factor for SVT is the presence of varicose
veins, which occurs in 62% of patients. Others factors
associated with SVT include: age 60 years old, obesity,
tobacco use, and a history of deep venous thrombosis
(DVT) or SVT. Factors associated with extension of SVT
include age 60 years old, male sex, and history of DVT.
The physical diagnosis of superficial thrombophlebitis
is based on the presence of erythema and tenderness in the
distribution of the superficial veins with the thrombosis
identified by a palpable cord. Pain and warmth are clinically
evident and significant swelling may be present even with-
out DVT. Patients may occasionally present with pain,
tenderness, and an erythemetous streak along the leg, but
without ultrasound evidence of DVT or SVT. In these
patients, the diagnosis of cellulitis or lymphangitis needs to
be considered.
While most attention has been focused on SVT of the
great saphenous vein (GSV), SVT of the small saphenous
vein (SSV) is also of clinical importance as it may progress
into popliteal DVT. In a group of 56 patients with SSV
SVT, 16% suffered from PE or DVT.136 Therefore, it is
crucial that patients with SSV SVT be managed employing
the same careful duplex examination, follow-up, and treat-
ment if the SVT approaches the popliteal vein.
Etiology
Virchow’s triad of altered blood flow, changes in the
vessel walls, and abnormal coagulation are recognized to
play a role in the etiology of thrombosis. While stasis and
trauma of the endothelium have been cited as a cause of
SVT, the importance of hypercoagulability has not been
well documented. Furthermore, since the DVT occurring
in association with SVT is often noncontiguous,136,138
direct extension of thrombosis from the superficial to the
deep venous system needs to be questioned and systemic
factors in the pathophysiology of SVT should be explored.
In order to determine whether a hypercoagulable state
contributes to the development of SVT, a number of
markers were determined in a population of patients with
acute SVT.139 All patients had a coagulation profile per-
formed that included: (1) protein C antigen and activity,
(2) activated protein C (APC) resistance, (3) protein S
antigen and activity, (4) antithrombin (AT) and (5) lupus-
type anticoagulant. Among 29 enrolled patients, 12 (41%)
were found to have abnormal results consistent with a
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combined SVT/DVT and seven of the patients (44%) with
isolated SVT were found to be hypercoagulable. These
findings suggest that patients with SVT are at an increased
risk of having an underlying hypercoagulable state.
Furthermore, while the importance of leukocyte-vessel
wall interactions, cytokines/chemokines, and other factors
in the development and resolution of DVT have been well
described, no similar data exists for the changes associated
with SVT. Although some authors have suggested that the
pathology underlying SVT may be analogous to DVT, this
viewpoint currently remains largely unsupported.
Diagnosis
It is supposed by a few authors that SVT is a benign
process that requires no further evaluation unless symp-
toms fail to spontaneously resolve. This is despite findings
that DVT associated with SVT may not be clinically appar-
ent.136
Duplex ultrasound scanning is now the initial test of
choice for the evaluation of SVT as well as the diagnosis of
DVT. The extent of involvement of the deep and superficial
systems can be accurately assessed utilizing this modality as
routine clinical examination may not be able to precisely
evaluate the proximal extent of involvement in either sys-
tem. As duplex imaging is accurate and venography may
contribute to phlebitis, venography is not routinely recom-
mended. Duplex imaging has shown concomitant DVT to
be present in 5% to 40% of patients with SVT. 136,140-143 It
is important to note that up to 25% of these DVTs may not
be contiguous with the SVT andmay be in the contralateral
lower extremity.136
Treatment
The location of the SVT determines the course of
treatment. The therapy may be altered should the SVT
involve tributaries of the GSV, distal GSV, or GSV of the
proximal thigh. Traditional treatment for SVT localized
in tributaries and the distal GSV has consisted of ambu-
lation, warm soaks, and nonsteroidal anti-inflammatory
agents.135,144,145 Surgical excision may play a role in rare
cases of recurrent thrombophlebitis despite maximal
medical management. However, such management does
not address the possibilities of thrombus extension or
concurrent DVT associated with proximal GSV SVT.
The progression of isolated superficial venous throm-
bosis to deep vein thrombosis has been evaluated. Among
263 patients with isolated superficial venous thrombosis by
duplex ultrasonography, 30 (11%) patients had docu-
mented progression to deep venous involvement.146 Pro-
gression from the greater saphenous vein in the thigh into
the common femoral vein (21 patients) was most common,
with 18 of these extensions noted to be nonocclusive and
12 having a free-floating component. At the time of the
follow-up examination, all 30 patients were being treated
without anticoagulation. As a result of this type of experi-
ence, follow-up duplex scanning 48 hours after presenta-
tion is often recommended to exclude progression.147Due to the recognized potential for extension into the
deep system and embolization, high saphenous ligation
with or without stripping is often recommended for SVT
within 1 cm of the saphenofemoral junction.148-151 In a
series of 43 patients who underwent ligation of the saphe-
nofemoral junction with and without local CFV thrombec-
tomy and stripping of the GSV, only two patients were
found with postoperative contralateral DVT, one of whom
had a PE.138 Eighty-six percent of the patients were dis-
charged within 3 days. Complications included wound
cellulitis in four patients and a wound hematoma in one.
While satisfactory results were noted in these instances,
several issues still remain unresolved. The question of
whether or not to strip the GSV in addition to high ligation
is not clearly addressed, although these patients do seem to
experience less pain once the SVT is removed. Ligation was
initially proposed to avert the development of deep venous
thrombosis by preventing extension through the saphe-
nofemoral junction. Since issues of noncontiguous DVT
and post-ligation DVT with PE are not addressed by this
therapy, alternative treatment options need to be explored.
A prospective nonrandomized study was conducted to
evaluate the efficacy of anticoagulation in the management
of saphenofemoral junction thrombophlebitis (SFJT).152
Duplex ultrasonography was performed before admission,
both to establish the diagnosis and to evaluate the deep
venous system. Patients were hospitalized, given a full
course of heparin treatment, and evaluated with duplex
ultrasound 2 to 4 days after admission to assess resolution
of SFJT and to reexamine the deep venous system. Patients
with SFJT alone and resolution of SFJT as documented by
duplex ultrasound scans were maintained on warfarin for 6
weeks. Those patients with SFJT and DVT were main-
tained on warfarin for 6 months.
Among 20 enrolled patients, eight (40%) had concur-
rent DVT, including four with unilateral DVT, two with
bilateral DVT, and two with development of DVT despite
anticoagulation. DVT was contiguous with SFJT in five
patients and noncontiguous in three patients. Seven out of
13 duplex ultrasound scans obtained at 2 to 8 months
follow-up demonstrated partial resolution of SFJT, five had
complete resolution, and one demonstrated no resolution.
There were no episodes of PE, recurrence, or anticoagula-
tion complications at maximum follow-up of 14 months.
Anticoagulation therapy to manage SFJT was effective in
achieving resolution, preventing recurrence, and prevent-
ing PE within the follow-up period. The high incidence of
DVT associated with SFJT suggests that careful evaluation
of the deep venous system during the course of manage-
ment is necessary.153
The appropriate management of SVT was further ad-
dressed in a prospective study consisting of 444 patients
randomized to six different treatment plans (compression
only, early surgery with and without stripping, low-dose
subcutaneous heparin, low-molecular-weight heparin, and
oral anticoagulation).154 Patients presenting with SVT and
large varicose veins without any suspected/documented
systemic disorder were included in this study. Exclusion
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nonambulatory status, bone/joint disease, problems re-
quiring immobilization, age 70 years, and patients with
superficial thrombophlebitis without varicose veins.
There was no significant difference in DVT incidence at
3 months among the treatment groups. After 3 and 6
months, the incidence of SVT extension was higher in the
elastic compression and saphenous ligation groups and
lowest is the stripping group. The cost for compression
solely was found to be the lowest, and the treatment arm
including LMWHwas found to be the most expensive. The
highest social cost (lost working days, inactivity) was ob-
served in subjects treated with stockings alone. However, as
the details of the treatment protocols were not specifically
identified, the results of this study are difficult to evaluate.
Furthermore, the exclusion criteria would eliminate many
of the patients diagnosed with SVT in a clinical practice and
the inclusion of almost any patient presenting with SVT,
regardless of its location makes the remaining groups quite
variable.
Meta-analysis of surgical vs medical therapy for isolated
above knee SVT has been attempted, but has not been
feasible due to the paucity of comparable data between the
two groups.155 This review suggested that although strip-
ping provides superior symptomatic relief, medical man-
agement with anticoagulants is somewhat superior with
respect to minimizing complications, and preventing sub-
sequent DVT and PE. Based on these data, the authors
suggest that anticoagulation is appropriate in patients with-
out contraindications.
Although proximal GSV SVT occurs not infrequently,
the best treatment regimen based on its underlying patho-
physiology and resolution rate remains controversial. More
recent investigations do offer some guidelines suggesting
that anticoagulation is more effective than venous ligation
in preventing DVT and PE.156 Further examination of the
unresolved issues involving SVT is fundamental.152
THE MANAGEMENT OF EXTREMITY VENOUS
TRAUMA
The early history of venous repair is not as well docu-
mented as for arterial injury. Schede is reported to have
performed the first successful lateral repair of a lacerated
femoral vein in 1882.157 One of the first wartime repairs of
a venous injury was by Goodman in 1918.158 However,
ligation of venous injuries was the accepted standard of care
duringWorldWar I. In an attempt to improve limb salvage,
Makins in 1919 recommended ligation of the uninjured
vein when an arterial injury was treated by ligation.159 In
1954, DeBakey and Simeone published their report on the
management of vascular injuries during World War II,
which included a short report on venous injuries.160 How-
ever, it was not until the Korean War that a more concerted
effort was made at perfecting the repair of venous inju-
ries.161 Rich extended Hughes observations in 1970 and
showed that repair of military venous injuries could be
performed safely. Later studies reinforced this practice, asboth early and late complications of venous repair were
lower than with ligation.
Incidence
Trauma is the fourth leading cause of civilian deaths in
the United States and the leading cause of death among
children and adults under age 45. Young males are at
greatest risk, with up to 30% of males sustaining injuries in
a single year. Only 20% of females sustain injuries over the
same time period. Males account for 72% of injury fatalities
and 56% percent of nonfatal injuries.162
Injury due to past military conflicts has involved exclu-
sively male soldiers, usually in their second to third decade
of life. In the Global War on Terrorism (GWOT), the
average age of wounded soldiers is 22 years (range 17 to 58
years). For vascular injuries specifically, the age range is 18
to 56 years with a mean of 28 years. The incorporation of
women into traditional combat roles has resulted in a shift
of wartime demographics. In the Global War on Terrorism,
women have accounted for 2% of all injuries and 3% of all
vascular injuries.
The true incidence of venous trauma is often difficult to
ascertain. It is not uncommon for surgeons to repair arterial
injuries and ligate the accompanying venous injury without
reporting it. As such, the true incidence of venous injury is
likely under reported. In the GWOT Vascular Trauma
Registry, a total of 200 arterial injuries have been docu-
mented during combat operations over a 4-year period. In
contrast, only 49 named venous injuries in 34 patients have
been reported during this same interval. Isolated venous
injuries are less common than combined arterial and venous
injuries, occurring in only 25% of GWOT patients. This is
very similar to previous reports on the incidence of venous
injuries suffered during wartime. Venous injuries ac-
counted for 39.4% of vascular injuries during the Korean
War, although the number occurring in association with
arterial injury is unknown.163 In their preliminary report on
vascular injuries suffered during the Vietnam War, Rich
noted that the majority (85.6%) of venous injuries occurred
in association with arterial injuries.164 Rich subsequently
published details of management of 1000 arterial injuries
from the Vietnam Vascular Registry in 1970. Three hun-
dred seventy seven (38%) of these arterial injuries were
associated with concomitant venous injuries.165,166
Several reports have documented the incidence of ve-
nous injuries in civilian trauma centers.165-170 The majority
(75%) of venous injuries occur in association with arterial
injuries. In these studies, 22% to 31% of arterial injuries
have an associated venous injury. Isolated venous trauma
occurs less frequently and accounts for 25% of venous
injuries.
Etiology
The majority of injuries in the United States are the
result of blunt trauma. Motor vehicle accidents are the
leading cause of injury death, accounting for one-third of
all fatal injuries. Injuries resulting from the use of firearms
are the second leading cause of injury death but the leading
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to death; 39% were homicide, 56% were suicide, and 5%
were unintentional.162 The majority of civilian firearm in-
juries are caused by low velocity handguns. In several series,
gunshot wound accounted for 50% to 100% of venous
injuries.168 Venous injuries from other causes, including
stab wounds (1% to 28%), blunt trauma (1% to 23%), and
shotguns (1% to 17%), occur much less frequently.
Fragmentation injuries have historically accounted for
the majority of military wounds.160, 165, 167, 168 The type of
fragmentation munition has changed over time from mor-
tars, to shells, to the present day improvised explosive
devices (IED). In the Global War on Terrorism, 68 (64%)
patients were wounded by IEDs, 27 (25%) were wounded
by gunshots, and 12 (11%) experienced blunt traumatic
injury.171
Distribution of injuries
The majority of civilian venous trauma occurs in the
extremities with a near equal distribution between upper
and lower extremities. Gaspar and Trieman172 documented
the distribution of civilian venous injuries: 17% superficial
femoral vein, 15% inferior vena cava, 15% internal jugular
vein, 14% brachial vein, and 8% popliteal vein. More recent
series report nearly 90% of venous trauma to occur in the
extremities. Smith173 reported 25% of venous injuries to
involve the iliac veins, 45% the femoral, 20% the popliteal,
and 10% the basilic veins.
Military injuries similarly largely involve the extremi-
ties. The majority of venous injuries during the Vietnam
conflict involved the lower extremity. Among these, Rich
reported that superficial femoral vein injuries occurred in
37% of patients with concomitant arterial injury. Injuries to
the popliteal vein occurred in 29.3% in comparison with the
common femoral vein in 5%. In contrast, venous injuries to
the upper extremity were less common; brachial and axillary
vein injuries accounting for 14% and 5% of venous injuries,
respectively. The modern use of body armor provides ex-
cellent protection from direct penetrating injury to the
chest, back, and abdomen. A recent review of military
injuries in the GWOT reveals that trauma to the head and
neck accounted for 31% of injuries, trunk 14%, lower
extremities 26%, and upper extremities 30%.171
Diagnosis
Extremity venous injuries are often difficult to identify.
Although life-threatening hemorrhage may be present, ve-
nous injuries are often difficult to diagnosis by physical
examination alone. Concomitant soft tissue swelling, inci-
sions and pain often preclude an adequate examination in
the acute and sub-acute setting. Slow, persistent hemor-
rhage from open soft tissue wounds may be noted. How-
ever, physical evidence of venous injury is most often rec-
ognized at the time of exploration for ischemia or
hemorrhage. Lacerations or transections of injured veins
are easily recognized but often overlooked. Furthermore,
venous injuries may require 12 to 24 hours to become
symptomatic, usually with the development of swelling,edema, or cyanosis. In cases of proximal venous injury,
swelling may be massive and in extreme situations may be
limb threatening and present as phlegmasia cerulean do-
lens.
Recognition of venous injuries in patients with non-life
or limb threatening trauma can be more challenging.
Rarely do patients undergo early radiologic evaluation for
the acute detection of venous injury. Delayed evaluation
often involves the use of B-mode or color flow duplex
(CFD) ultrasonography or contrast phlebography. Other
noninvasive tests such as plethysmography are too nonspe-
cific to detect injury and are not useful in the modern
setting.
Ultrasonography is the study of choice for the initial
detection and evaluation of venous thromboses associated
with trauma. The loss of spontaneous venous flow, respira-
tory variation, and compressibility confirm venous throm-
bosis. Gagne174 reported that CFD detected seven of eight
(88%) venous injuries in 37 patients with penetrating prox-
imity extremity trauma. Venography was technically diffi-
cult to perform in this patient population and failed to
detect four femoral-popliteal vein injuries. Ultrasonogra-
phy may, however, be less sensitive and more labor inten-
sive in determining the details of venous outflow from an
injured extremity. Furthermore, in the current GWOT, the
use of ultrasonography has often been limited by external
fixators and large soft tissue defects associated with IED
injuries.
Ascending phlebography is an excellent technique for
determining venous injury as well as documenting the
status of extremity venous outflow.175 The use of multiple
tourniquets for assessment of the deep venous system is
useful in understanding lower extremity venous outflow.
Spiral CT venography is a new technique that may have
some utility in the setting of venous injury. Not only is this
technique sensitive for the detection of venous thrombosis,
it also provides information on injuries to associated struc-
tures.176 Finally, although somewhat time intensive, MRI
can also be a useful adjunct in venous diagnosis.177 Neither
of these techniques, however, are useful in the trauma
patient with retained missile fragments.
Pathophysiology of venous trauma
During World War I, improved limb salvage was re-
ported for venous ligation in the presence of arterial liga-
tion.159 DeBakey and Simeone, in contrast, were unable to
corroborate these observations in vascular injuries occur-
ring during WWII. This controversy stimulated early re-
searchers at Walter Reed Army Institute of Research to
develop animal models for further investigation of the
effect of venous ligation on limb physiology.
Early canine hind limb models suggested a sudden and
temporally related decrease in arterial inflow accompanying
acute venous occlusion.178 Using the same model, Hobson
subsequently confirmed these findings and further noted
that femoral arterial flow improved after 48 hours.179
These findings were attributed to increased venous return
through recruitment of collaterals. They concluded that
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tients suffering combined arterial and venous extremity
injuries, especially in the first 48 hours.
In the event that surgeons were forced to manage
venous injuries by ligation, investigators at the Walter Reed
Army Institute of Research Investigations searched for
alternative methods to preserve limb perfusion. Among the
findings from a canine model of femoral venous ligation
was that arterial inflow could be improved with phenoxy-
benzamine.180 Improvement of limb perfusion was also
verified in a primate model of venous ligation after lumbar
sympathectomy.181 These investigations give surgeons al-
ternate methods of avoiding arterial ischemia in the face of
acute venous occlusion.
Treatment
Most surgeons agree that the best management of
major axial vein injuries is to repair them if possible. Clearly,
even complex repairs are possible in patients who have
minimal injuries and can tolerate additional operative time.
In contrast, for the patient in extremis where decisions of
life over limb need to be made, repair of even major
extremity veins becomes less important. The controversy
regarding repair vs ligation of venous injuries thus mainly
involves patients who are severely injured but not in life or
death situations.
Repair of venous injuries. Until the Korean War,
ligation had been the accepted historical method of man-
aging venous injuries. After successfully repairing arterial
injuries using Potts clamps for vascular control, the US
Army Surgical Research Team headed by Dr Carl Hughes
began attempting the repair of venous injuries.161,182 In
1954, Hughes reported successful repair of 13 venous
injuries occurring in patients with concomitant arterial
injury. The success of these reports stimulated Rich et al to
continue investigation into the repair of venous injuries
during the VietnamWar. They reported the success of their
methods in several reports.157,165,183-190 Following these
results, several centers have now reported their results for
repair of venous injuries in civilian populations.169,191-195
The repair of venous injuries is largely performed by
lateral suture repair. During the Korean War, Hughes163
reported using lateral suture repair in the management
of 12 of 13 venous repairs. Lateral venorraphy was
similarly used in 85% of venous repairs during the Viet-
nam War. Early data from the war in Iraq also seems to
show that lateral venorraphy has been most often em-
ployed for the management of venous injuries. This
trend is reflected in reports on the management of
civilian venous trauma. Published series report that 17%
to 43% of venous injuries are managed by simple lateral
suture.169,170,172,173,191,193,194 The success of this tech-
nique ranges from 76% to 93% during short-term
follow-up.
End to end anastomosis and venous patch angioplasty
are useful techniques for the repair of injured veins without
a large segmental loss. Hughes reported the first end-to-
end anastomosis for the repair of venous injuries in 1954.Rich subsequently reported that 15% of military venous
injuries were managed using end-to-end anastomosis
(8.1%), interposition vein grafts (4.0%), or vein patch an-
gioplasty (2.4%). Hobson169 reported the highest use of
end to end repair in civilian femoral vein injuries, with a
patency of 74% in the early postoperative period.
Interposition grafting is the most popular method of
repair for injuries associated with a long segment loss of
the injured vein. In general, the contralateral great sa-
phenous vein is used in a reverse fashion. Using the
ipsilateral vein may compromise venous outflow in the
injured extremity. In Rich’s series, 4% of patients re-
ceived vein interposition grafts for military injuries. Early
reports from the current military conflict indicate that
this technique is rarely utilized. Interposition grafting
accounts for 11% to 42% of venous repairs in several
civilian series.169,170,172,191,193,194 However, the results
of interposition grafting have been somewhat disap-
pointing; 30-day patency rates being only 40% to 75%.
Extremity injuries occasionally result in loss of a large
segment of vein in patients without suitable autologous
conduit. The efficacy of alternative conduits in these situa-
tions has been previously investigated. Using a canine
model, Hobson reported on the use of collagen tubes196
and fresh venous homografts. Wright197 similarly reported
their experience with bovine heterografts in a canine
model. The use of prosthetic conduits, such as polytetra-
fluoroethylene (PTFE), for venous bypass in civilian trauma
patients has been more recently reported.194,198,199 The
use of prosthetic conduits to manage military vascular
injuries has been reported to be useful when other conduits
have not been suitable maintaining limb perfusion.200 Ex-
perimental studies support these observations and have
shown PTFE to have a lower rate of infection and compli-
cations in heavily contaminated wounds compared with
autologous vein.199,201,202 Prosthetic conduits may be
most useful when the great saphenous vein is of inadequate
size, poor quality, or needed for venous outflow in the
multiply injured patient. However, the long-term patency
of PTFE when used for traumatic venous reconstruction is
very disappointing. Of 30 PTFE grafts placed in the venous
system, Feliciano reported that 100% thrombosed in the
early postoperative period.
Several authors have reported the use of complex ve-
nous repairs.168,194,203-205 Rich157 first reported using a
cross femoral venous bypass for themanagement of military
venous injuries 1974. The use of panel or spiral grafts for
military injuries has not been reported. Such complex ve-
nous repairs have, however, been described for the man-
agement of civilian venous trauma.191,193,205 In their se-
ries, Pappas191 reported that 8% of patients received spiral
vein grafts and 11% panel grafts in the iliac, common
femoral, or popliteal arteries. However, the patency of
complex venous repairs is significantly lower than simpler
techniques. Meyer193 report early thrombosis of 50% of
these repairs. Such results have led several authors to ques-
tion the utility of spiral and panel grafts in the management
of venous trauma.
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plex venous repairs, adjuncts for improving these results
have been investigated. The use of arteriovenous fistulas as
an adjunct to venous interposition grafts has been evaluated
in a canine model.206 These studies indicated that con-
struction of an H-type arteriovenous fistula at the distal
anastomosis improved patency in comparison with a side-
to-side configuration. In either case, construction of an
arteriovenous fistula at the distal anastamosis improved
venous bypass patency.
Potential complications of venous repair, such as
pulmonary emboli and deep venous thrombosis, have
been cited as reasons to avoid these techniques. How-
ever, numerous military and civilian series have found a
low incidence of venous thromboembolic complica-
tions (0% to 1%) in patients managed by venous
repair.163,169,185,189,194
Ligation of venous injuries. Ligation has been the
principle method of managing venous injuries for centu-
ries. Although ligation continued to be used during the
initial years of the Korean War, Hughes161,182,207 and
Spencer208 began to explore the possibilities of venous
repair. Despite this progress, increasing observations
seemed to emphasize the lack of serious complications
associated with venous ligation.209 Several reports from
civilian trauma populations now suggest that immediate
side effects of venous ligation are few and can be mini-
mized by the liberal use of fasciotomy and postoperative
limb elevation.168,210,211
The effects of femoral or popliteal vein ligation might
also be extrapolated from recent reports on harvesting the
femoropopliteal vein for arterial reconstruction.209
Wells212 found that less than one third of harvested limbs
had edema and no patient had major chronic venous
changes or venous claudication after a mean follow-up of
37 months. The development of severe venous hyperten-
sion after complete deep vein harvest below the adductor
hiatus required adjunctive measures such as fasciotomy in
20.7% of limbs. In contrast, fasciotomies were not required
in patients undergoing subtotal deep vein harvest ending
above the adductor hiatus. Fasciotomies were also per-
formed in 76% of limbs undergoing concurrent ipsilateral
GSV) and deep vein harvest, compared with 11.7% of
patients undergoing deep vein harvest alone.213 Although
these observations suggest that the morbidity associated
with elective harvesting of the femoropopliteal vein conduit
is acceptable, this may not accurately reflect the physiologic
situation in the acutely injured extremity with extensive soft
tissue injuries, acute interruption of lymphatics, and com-
promised venous drainage.
The acute physiologic changes associated with proxi-
mal venous obstruction of the lower extremity have
been documented both clinically214,215 and experimen-
tally.180,181,216 Opponents have argued that the morbidity
associated with venous ligation is not always inconsequen-
tial. In a 1974 review of 125 limbs amputated after popli-
teal artery trauma, Rich217 found that amputation resulted
from acute venous hypertension following venous ligationin the presence of a patent arterial repair in 19 (15%). As in
these cases, predicting which patient will develop phlegma-
sia cerulean dolens is not always possible. Certainly, pa-
tients with ligation of the common iliac, common femoral,
or popliteal veins are at highest risk due to the lack of
preexisting collateral channels at these junctures. Massive
fluid shifts typically accompany proximal venous ligation;
often reaching several liters within a few days.218 Shock due
to these fluid losses has been reported to occur in up to one
third of patients with phlegmasia cerulea dolens. Clearly,
this phenomenon will make hypotensive patients with mul-
tisystem trauma worse.
Despite these observations, the long-term effects of
venous ligation are not always dramatic and life threaten-
ing. Rich reported significant postoperative edema in 29 of
57 patients (50.9%) after ligation of popliteal vein injures.
In contrast, Timberlake219 reported no difference in the
incidence of lower extremity edema between patients
whose popliteal vein injury was ligated or repaired.
Outcome after venous injury
Several studies have reported follow-up results 6 to 20
years after venous injury.204,220-222 Patency rates for simple
repairs range from 67% to 100% in long-term follow-up.
However, few studies have examined the effect of traumatic
venous repairs on postoperative venous function. The ma-
jority of these studies have been unable to demonstrate a
difference in venous hemodynamics between patients man-
aged by repair vs ligation using color flow duplex, photop-
lethysmography, impedence plethysmography, or air pleth-
ysmography.203,221,223
Several institutions have documented long-term ad-
verse effects of fasciotomy on the development of chronic
venous insufficiency.203,224,225 These observations provide
yet another possible explanation for the development of
venous insufficiency in the lower extremity trauma patient.
Recommendations
Injuries to major proximal veins of either the upper or
lower extremity should be repaired if at all possible. Specif-
ically, the axillary, subclavian, common iliac, external iliac,
common femoral, and popliteal veins should be repaired.
Even short-term patency of these veins will help avoid
massive distal swelling distal and possible development of a
compartment syndrome. There is currently no evidence
that repair of venous injuries leads to a higher incidence of
venous thromboembolic complications. If repair of these
injured veins is not safe or possible, ligation is the obvious
alternative and should be performed. In these cases, the
surgeon should expectmassive acute extremity swelling and
manage it accordingly with fasciotomy and leg elevation.
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Appendix
Evidence-based guideline recommendations
With few exceptions, patients with DVT or PE are
treated similarly.
Initial treatment of patients with venous thromboem-
bolism:
Initial regimen:
● For patients with objectively confirmed DVT or PE,
short-term treatment with SC LMWH or IV UFH is
recommended (Grade A). SC UFH may be used in
DVT patients (Grade A);
● or patients with a high clinical suspicion of DVT or PE,
treatment with anticoagulants while awaiting the out-
come of diagnostic tests is suggested (Grade C);
● In patients with DVT or acute nonmassive PE, LMWH
over UFH is recommended (Grade A). Uncomplicated
DVT patients may be treated as an outpatient.
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with LMWH, routine monitoring with antifactor Xa
levels is not recommended (Grade A);
● In patients with severe renal failure, IV UFH over
LMWH is suggested (Grade C);
Duration of initial treatment:
● In acute DVT or PE, initial treatment with LMWH or
UFH for at least 5 days is suggested (Grade C).
Commencing vitamin-k-antagonist therapy:
● Initiation of VKA together with LMWH or UFH on
the first treatment day and discontinuation of heparin
when the INR is stable and 2.0 is recommended
(Grade A).
Adjunctive initial therapy
Thrombolytic therapy:
● In patients with DVT or PE, the routine use of sys-
temic thrombolytic treatment is not recommended
(Grade A).
● In selected DVT patients, such as those with massive
ileofemoral DVT at risk of limb gangrene secondary
to venous occlusion, IV thrombolysis is suggested
(Grade C).
● In selected patients with PE, systemic administration
of thrombolytic therapy is suggested (Grade B). For
PE patients who are hemodynamically unstable, use of
thrombolytic therapy is suggested (Grade B). For pa-
tients with PE who receive thrombolytic regimens, use
of thrombolytic regimens with a short infusion time
over those with prolonged infusion times is suggested
(Grade C).
● In PE patients, it is suggested that local administration
of thrombolytic therapy via a catheter should not be
used (Grade C).
● In patients with DVT, the routine use of catheter-
directed thrombolysis is not suggested (Grade C). In
DVT patients, confining catheter-directed thrombol-
ysis to selected patients such as those requiring limb
salvage is suggested (Grade C).
Nonsteroidal anti-inflammatory agents:
● For the initial treatment of DVT, the use of nonsteroi-
dal anti-inflammatory agents is not recommended
(Grade B).
Ambulation:
● For DVT patients, it is recommended that these
patients be permitted ambulation as tolerated
(Grade B).
Long-term treatment of patients with venous
thromboembolism
Intensity of long-term vitamin-k-antagonist therapy
● In patients with DVT or PE, adjusting the dose of
VKA to maintain a target INR of 2.5 (range, 2.0 to3.0) for all treatment durations is recommended
(Grade A). High-intensity VKA therapy (INR range,
3.1 to 4.0) is not recommended (Grade A). Low-
intensity therapy (INR range, 1.5 to 1.9) compared
with INR range of 2.0 to 3.0 is not recommended
(Grade A).
Long-term LMWH treatment
● For most patients with DVT or PE and concurrent
cancer, treatment with LMWH for at least the first 3 to
6 months of long-term treatment is recommended
(Grade A). For these patients, anticoagulant therapy
indefinitely or until the cancer is resolved is suggested
(Grade C).
Duration of long-term vitamin-k-antagonist therapy
Transient (reversible) risk factors:
● For patients with a first episode of DVT or PE secondary
to a transient (reversible) risk factor, long-term treatment
with a VKA for at least 3 months over treatment for
shorter periods is recommended (Grade A).
Idiopathic:
● For patients with a first episode of idiopathic DVT or
PE, treatment with a VKA at least 6 to 12 months is
recommended (Grade A).
● Considering patients with first-episode idiopathic
DVT or PE for indefinite anticoagulant therapy is
suggested (Grade A).
Presence of a thrombophilia:
● For patients with a first episode of DVT or PE who
have documented antiphospholipid antibodies or who
have two or more thrombophilic conditions (eg, com-
bined factor V Leiden and prothrombin 20210 gene
mutations), treatment for 12 months is recommended
(Grade C). Indefinite anticoagulant therapy in these
patients is suggested (Grade C).
● For patients with a first episode of DVT or PE who
have documented deficiency of antithrombin, defi-
ciency of protein C or protein S, or the factor V Leiden
or prothrombin 20210 gene mutation, homocysteine-
mia, or high factor VIII levels (90th percentile of
normal), treatment for 6 to 12 months is recom-
mended (Grade A). Indefinite therapy as for patients
with idiopathic thrombosis is suggested (Grade C).
Recurrent venous thromboembolism:
● For patients with two or more episodes of objectively
documented DVT or PE, indefinite treatment is rec-
ommended (Grade A).
Indefinite anticoagulant treatment:
● In DVT or PE patients who receive indefinite antico-
agulant treatment, the risk-benefit of continuing such
treatment should be reassessed in the individual pa-
tient at periodic intervals (Grade C).
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● In patients with DVT or PE, repeat testing with com-
pression ultrasonography for the presence or absence of
residual thrombosis or measurement of plasma D-dimer
is suggested (Grade C).
Vena caval filter
● For most patients with DVT, the routine use of a vena
cava filter in addition to anticoagulants is not recom-
mended (Grade A).
● In DVT or PE patients the placement of an inferior
vena caval filter in patients with a contraindication for,
or a complication of anticoagulant treatment is sug-
gested (Grade C), as well as in those with recurrent
thromboembolism despite adequate anticoagulation
(Grade C).
Catheter interventions
● For most patients with PE, use of mechanical ap-
proaches is not recommended (Grade C). In selected
highly compromised patients who are unable to re-
ceive thrombolytic therapy or whose critical status
does not allow sufficient time to infuse thrombolytic
therapy, use of mechanical approaches is suggested
(Grade C).
Thrombectomy and embolectomy
● In patients with DVT, the routine use of venous
thrombectomy is not recommended (Grade C).● In selected patients such as patients with massive il-
eofemoral DVT at risk of limb gangrene secondary to
venous occlusion, venous thrombectomy is suggested
(Grade C).
● For most patients with PE, pulmonary embolectomy is
not recommended (Grade C). In selected highly com-
promised patients who are unable to receive thrombo-
lytic therapy or whose critical status does not allow
sufficient time to infuse thrombolytic therapy, pulmo-
nary embolectomy is suggested (Grade C).
Post-thrombotic syndrome
● The use of an elastic compression stocking with a
pressure of 30 to 40mmHg at the ankle during 2 years
after an episode of DVT is recommended (Grade A).
● A course of intermittent pneumatic compression for
patients with severe edema of the leg due to PTS is
suggested (Grade B).
● The use of elastic compression stockings for patients
with mild edema of the leg due to the PTS is suggested
(Grade C).
● In patients with mild edema due to PTS, administra-
tion of rutosides is suggested (Grade B).
Adapted from Buller HR, Agnelli G, Hull RD, Hyers
TM, Prins MH, Raskob GE. Antithrombotic therapy for
venous thromboembolic disease: the Seventh ACCP Con-
ference on Antithrombotic and Thrombolytic Therapy.
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